



2018-07-01

# The Diversity Found Among Carbapenem-Resistant Bacteria

Galen Edward Card  
*Brigham Young University*

Follow this and additional works at: <https://scholarsarchive.byu.edu/etd>

 Part of the [Microbiology Commons](#)

---

## BYU ScholarsArchive Citation

Card, Galen Edward, "The Diversity Found Among Carbapenem-Resistant Bacteria" (2018). *All Theses and Dissertations*. 6949.  
<https://scholarsarchive.byu.edu/etd/6949>

This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in All Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [scholarsarchive@byu.edu](mailto:scholarsarchive@byu.edu), [ellen\\_amatangelo@byu.edu](mailto:ellen_amatangelo@byu.edu).

The Diversity Found Among Carbapenem-Resistant Bacteria

Galen Edward Card

A thesis submitted to the faculty of  
Brigham Young University  
in partial fulfillment of the requirements for the degree of  
Master of Science

Richard A. Robison, Chair  
Kim L. O'Neill  
Joel S. Griffitts

Department of Microbiology and Molecular Biology  
Brigham Young University

Copyright © 2018 Galen Edward Card

All Rights Reserved

## ABSTRACT

### The Diversity Found Among Carbapenem-Resistant Bacteria

Galen Edward Card

Department of Microbiology and Molecular Biology, BYU  
Master of Science

This work will look at two factors that add to the diversity of carbapenem resistant bacteria. First, it focuses on the diversity of carbapenemase resistance plasmids. 446 plasmids were characterized by size, gene content and replicon groups. We identified that on average, over 30% of the encoded proteins on each plasmid have an unknown function. Plasmid sizes ranged from 1.6kb to 500kb, with an average of around 100kb and median of 80kb. Additionally, six replicon groups account for 80% of all the carbapenemase resistance plasmids. We also highlight the lack of data available for carbapenemase carrying plasmids from bacterial genera other than *Escherichia* and *Klebsiella*, and plasmids that carry the New Delhi metallo- $\beta$ -lactamase or the Verona-integron encoded metallo- $\beta$ -lactamase.

Second, we characterized the  $\beta$ -lactamase diversity of a single carbapenemase resistant *Klebsiella pneumoniae*. This isolate encodes six distinct  $\beta$ -lactamases, all of which are functional, and three of which are redundant. Additionally, we determined that the CTX-M-15 cephalosporinase imparts a greater fitness when grown in aztreonam (a monobactam) than ceftazidime (a cephalosporin). Finally, we show that individually, these  $\beta$ -lactamases do not account for the elevated levels of resistance seen in the parent strain, indicating that the passive resistance mechanisms (i.e. efflux pumps, altered membrane porins) may play a larger role than originally thought.

Keywords: Antimicrobial resistance,  $\beta$ -lactamase, carbapenem resistant *Enterobacteriaceae*, *Klebsiella pneumoniae*, Extended-spectrum  $\beta$ -lactamase, ESBL, plasmid, horizontal gene transfer

## ACKNOWLEDGEMENTS

I would like to take this space to express my thanks to all who have helped me in my pursuit of this Master's. First, I'd like to thank my committee. Dr. Robison, thank you for providing an environment where I could grow and develop individual thought in my research. Dr. Griffiths, thank you for your help and guidance through my struggles with the molecular cloning work. Dr. O'Neill, thank you for your key insights in all the committee meetings, your input helped me address issues that I would not have noticed on my own.

Second, my sincerest thanks to my family. Amy and Liam, coming home to you makes going back to the lab the next day easier. For my parents, thank you for your support and glowing pride in me. To the Underwoods, thank you for providing a place for us to live and more, allowing me to focus on academics.

Third, thank you to my fellow graduate students in the Robison Lab and the MMBio Department. Your friendship and assistance has been immeasurable.

## TABLE OF CONTENTS

TITLE PAGE .....	i
ABSTRACT.....	ii
ACKNOWLEDGEMENTS.....	iii
TABLE OF CONTENTS.....	iv
LIST OF TABLES.....	vii
LIST OF FIGURES .....	viii
INTRODUCTION .....	1
The Rise of Antimicrobial Resistance.....	1
<i>The use of antimicrobials in agriculture</i> .....	1
<i>The clinical misuse of antimicrobials</i> .....	2
<i>Spread of antimicrobial resistance within a bacterial population</i> .....	2
β-lactams and Their Hydrolases .....	5
<i>Extended-Spectrum β-lactamases</i> .....	8
Carbapenems and Their Hydrolases .....	11
<i>Klebsiella pneumoniae carbapenemase</i> .....	11
<i>New-Delhi metallo-β-lactamase</i> .....	12
<i>Verona integron-encoded metallo-β-lactamase</i> .....	12
<i>Imipenem resistant Pseudomonas metallo-β-lactamase</i> .....	12
Summary.....	13
CHAPTER 1 .....	14
ABSTRACT .....	14
BACKGROUND.....	14

METHODS .....	16
Sequence acquisition.....	16
Plasmid gene composition .....	17
Incompatibility group/Replicon typing and plasmid characterization.....	17
Statistical analyses .....	17
RESULTS .....	18
Plasmid gene composition .....	18
Plasmid Incompatibility group/Replicon typing.....	20
DISCUSSION.....	20
Funding.....	23
Acknowledgements .....	23
Conflicts of Interest .....	23
CHAPTER 2 .....	24
ABSTRACT .....	24
INTRODUCTION.....	24
METHODS.....	25
Genome sequencing, assembly, and annotation .....	25
β-lactamase cloning .....	26
Growth curve analysis.....	27
Statistical analysis.....	29
RESULTS.....	29
<i>Klebsiella pneumoniae</i> 1300761 possesses six β-lactamase-encoding genes.....	29
Resistance profiles of β-lactamase clones.....	29

β-lactam preferences for a single β-lactamase .....	30
Growth of the parent strain <i>K. pneumoniae</i> 1300761 is not inhibited by any β-lactam tested .....	33
DISCUSSION.....	33
ACKNOWLEDGEMENTS.....	34
SUMMARY .....	35
REFERENCES .....	36
APPENDIX A.....	46
APPENDIX B.....	57
Supplementary Bioinformatics Methods.....	57
APPENDIX C .....	99
APPENDIX D.....	100
APPENDIX E .....	101

## LIST OF TABLES

TABLE 1: The four classes of $\beta$ -lactam antibiotics and examples of each.....	6
TABLE 2: PCR primers for the cloning of $\beta$ -lactamase genes found in <i>Klebsiella pneumoniae</i> 1300761.....	28
TABLE 3: Key Words used to characterize CR-plasmid gene content.....	46
TABLE 4: CR-plasmid accession numbers .....	99
TABLE 5: Percent of plasmids belonging to each incompatibility group.....	100
TABLE 6: Relative abundance of incompatibility groups among carbapenemase-carrying plasmids. ....	101



## LIST OF FIGURES

FIGURE 1: Acquisition of antibiotic resistance gene within a transposable element.....	4
FIGURE 2: The four classes of $\beta$ -lactam antibiotics.....	7
FIGURE 3: $\beta$ -lactamase mediated hydrolysis of a cephalosporin.....	9
FIGURE 4: ESBL variants of TEM-1.....	10
FIGURE 5: Characteristics of carbapenemase-encoding plasmids.....	19
FIGURE 6: Relative abundance of incompatibility groups among plasmids.....	21
FIGURE 7: Growth curves grouped by growth conditions.....	31
FIGURE 8: Growth curves of the $\beta$ -lactamase clones.....	32

## INTRODUCTION

### The Rise of Antimicrobial Resistance

Since the dawn of the antimicrobial era in 1937 with the introduction of sulfonamides, and the subsequent resistance of microbes arising in 1942, we have been in an arms race against rapidly evolving bacteria (1). Like clockwork, with each implementation of a new antimicrobial, resistance to that antimicrobial has appeared shortly thereafter (2). During the past several decades we have seen the rapid emergence of multi-drug resistant (MDR) and pan-resistant bacteria (3). With limited treatment options for these MDR organisms, and no treatments for pan-resistant organisms, we are facing what is being called the post-antimicrobial era, a time in which a seemingly routine infection presents the threat of death. Indeed, this threat is real with fatality rates of certain MDR bacteria reaching 50% (4). Many factors play a part in the rise and dissemination of antimicrobial resistance. The most important are the use of antimicrobials in agriculture, the clinical misuse of antimicrobials, and the facile spread of resistance within a bacterial population.

*The use of antimicrobials in agriculture* – What started as a prophylactic measure to prevent loss of livestock and enhance weight gain of food animals has led to a burgeoning healthcare crisis (5). Furthermore, it has been predicted that antibiotic use in agriculture will increase by 67% from 2010 through 2030, despite the restrictions that have been placed on their use in many countries (6). When antimicrobials are mixed in livestock feed, they quickly become diluted as rain and runoff mixes with the feed. The diluted antimicrobial then reaches a sub-inhibitory concentration that doesn't kill some bacteria. Instead, it creates a selective pressure that kills a majority, allowing the few bacteria that can cope with the diluted antimicrobials propagate (7-10). This leads to rapid mutation and evolution as the bacteria improve their


resistance mechanisms to the antimicrobials. This then contributes to the human healthcare crisis as the zoonoses found on farms enter the human population through contaminated food products (11-13). Studies have shown that many species within the *Enterobacteriaceae* family that are found on farms have also been found on hospital surfaces and isolated from infected patients (14-17), giving credence to the threat posed to human health from the use of antimicrobials in agriculture.

*The clinical misuse of antimicrobials* – The misuse of antimicrobials in a clinical setting has two parts: the prescription of antimicrobials for a non-susceptible infection and prescribing a prolonged antimicrobial regimen (2, 18-20). Since antibiotics have no effect on viral infections, using them to treat viral infections only provides an opportunity to select for resistant isolates and should not be done. Second, the World Health Organization has shown through current research that prolonged courses of antimicrobials may increase the rates of antimicrobial resistance (2, 21). This persistent exposure to antimicrobials provides an environment wherein the bacteria have time to mutate and develop resistance to the antimicrobial. Proper antimicrobial stewardship in the healthcare setting is essential if we are to slow the spread of resistance.

*Spread of antimicrobial resistance within a bacterial population* – The third, and perhaps most important, factor that contributes to the rise and dissemination of antimicrobial resistance is the facile transfer of antimicrobial resistance genes within a bacterial community. Many of the antimicrobial resistance genes are found within mobile genetic elements such as plasmids and transposons. Transposons, in their simplest form, are stretches of DNA that encode machinery that can replicate, excise, and integrate these regions into other DNA sequences (22). Throughout their “lifespan”, transposons can acquire genes from their host chromosome and transfer them to plasmids (2, 18, 23-25). These genes can then be passed within a bacterial community as the

plasmids are shared. The opposite can also occur. Resistance genes can be transferred from a plasmid to the host's chromosome. This is a permanent event. Once the resistance gene has entered the chromosome, there is no straightforward way to eliminate the gene. On the other hand, plasmids are more transient, and there are methods that can 'cure' bacterial strains of plasmids (26-28). Figure 1 shows a possibility of how a transposon may acquire and transfer resistance genes as it inserts and removes itself from the area surrounding the gene.

As mentioned, transposons can, and often do, integrate into plasmids. A plasmid is a circular piece of extra-chromosomal DNA that is maintained and replicated along with the chromosome. Ranging in size from less than 1kb to well over 200kb, they have the capability of carrying numerous genes. These genes can fall into several categories ranging from basic housekeeping or metabolism genes, to critical virulence genes, like the toxins responsible for the lethality of *Bacillus anthracis*. One unique feature of some plasmids is that they also carry a cluster of *tra* genes, or transfer genes. These genes provide a means for the plasmid to pass promiscuously between strains of bacteria via horizontal transfer (2, 24). Plasmids can also carry genes that cause the host bacterium to die if it does not retain the plasmid (29-32). These 'plasmid addiction systems' function using a toxin/antitoxin strategy. Encoded on the plasmid is a toxin, and its corresponding antitoxin. Of these two protein products, the toxin component is more stable. If the plasmid is lost from the host strain, the levels of antitoxin within the cytoplasm will decrease as it degrades quicker than the toxin. This in turn leaves the toxin free to exert its lethal effects within the cell. All these mechanisms contribute to the facile spread and maintenance of antimicrobial resistance among bacterial populations.



The next transposition event can now choose any of the three LTRs present as it excises from the DNA. There are two possible events that would transfer the antibiotic resistance to foreign DNA.

FIGURE 1: Acquisition of antibiotic resistance gene within a transposable element. 1) Wild type DNA receives transposon. 2) A transposition event occurs, leaving a scar upstream of an antibiotic resistance gene as the transposon jumps downstream. 3) A second transposition event leads to two possible scenarios where the antibiotic resistance gene is transferred to another mobile genetic element such as a plasmid. Other recombination events are possible; however, they do not transfer the antibiotic resistance to the new DNA.

## $\beta$ -lactams and Their Hydrolases


The most widely known class of antibiotics and one for which resistance has become a grave issue due to the reasons mentioned, are the  $\beta$ -lactams. So named due to the presence of a  $\beta$ -lactam ring as the central chemical backbone, these antibiotics have a four-membered ring, as depicted in Figure 2. Table 1 lists the four classes of  $\beta$ -lactams and provides examples of each. The first  $\beta$ -lactam antibiotic is also the original antibiotic discovered, penicillin. Penicillin and its derivatives, along with all  $\beta$ -lactams employ the same mode of action to kill bacteria. Known as cell wall inhibitors,  $\beta$ -lactams bind to and inactivate the penicillin-binding protein. This protein, so named for penicillin's action against it, is responsible for covalently cross-linking peptidoglycan during bacterial cell wall synthesis. Without cross-linked peptidoglycan, cell morphology becomes more elongated, cell structure is fragile, and bacterial lysis occurs in most environments as water rushes into the cell to balance osmolarity. However, as with all antibiotics, bacterial resistance to  $\beta$ -lactams quickly arose after their discovery.

This resistance is mediated by a  $\beta$ -lactam specific hydrolase, or a  $\beta$ -lactamase, of which there are several types and various classification schemes. The simplest classification was implemented by Ambler in 1980, in which  $\beta$ -lactamases were grouped based on protein sequence (33). His scheme divides the  $\beta$ -lactamases into four classes, Ambler Classes A through D. Classes A, C, and D are serine-mediated  $\beta$ -lactamases (34). The class B  $\beta$ -lactamases are metallo- $\beta$ -lactamases (MBLs) and require a zinc ion to assist in the hydrolysis reaction (35).


Figure 3 (adapted from original (36)) depicts how a serine  $\beta$ -lactamase catalyzes the hydrolysis of a  $\beta$ -lactam. First, a serine residue of the  $\beta$ -lactamase will attack the carbonyl, pushing electrons of the double bond onto the oxygen (Step 1). This leaves a highly unstable

TABLE 1: The four classes of  $\beta$ -lactam antibiotics and examples of each.





$\beta$ -lactam Antimicrobials		
Penicillins	Penicillin	Penicillin G Penicillin V
	Aminopenicillin	Ampicillin Amoxicillin
	Carboxypenicillin	Carbenicillin Ticarcillin
	Penicillinase-resistant penicillin	Methicillin Nafcillin Oxacillin Cloxacillin
Monobactams	Aztreonam	
Cephalosporins	1 <sup>st</sup> Generation	Cephalothin Cephalexin Cefazolin
	2 <sup>nd</sup> Generation	Cefamandole Cefaclor Cefuroxime Cefoxitin Cefotetan
	3 <sup>rd</sup> Generation	Ceftriaxone Ceftazidime Cefotaxime Ceftozominem Ceftibuten
	4 <sup>th</sup> Generation	Cefepime Cefpirome
Carbapenems	Imipenem Doripenem Ertapenem Meropenem	




Penicillin



Cephalosporin



Monobactam



Carbapenem





FIGURE 2: The four classes of  $\beta$ -lactam antibiotics.

The core  $\beta$ -lactam is highlighted in red. Each derivative within each class will deviate in the R groups. When hydrolyzed, the bond between the nitrogen and the carbonyl carbon is cleaved. A few examples are given.



negatively charged oxygen. To reduce this strain, the electrons collapse back down, and orbital resonance dissipates the energy across the molecule, opening the  $\beta$ -lactam ring in the process (Step 2). Then a two-step proton transfer from water to the serine residue of the  $\beta$ -lactamase resolves the hydrolysis reaction (Steps 3-5).

The most commonly encountered  $\beta$ -lactamases are the class A  $\beta$ -lactamases TEM (named for the patient in which it was first identified, Temoniera) and SHV (sulfhydryl variable) types, with 90% of the ampicillin resistance encountered in *E. coli* mediated by TEM-1 (18). And due to their widespread prevalence,  $\beta$ -lactamase inhibitors have been developed. These inhibitors do not affect the activity of penicillin binding protein, and administration of these in conjunction with a  $\beta$ -lactam can kill the bacteria. However, these inhibitors are only effective against the serine mediated  $\beta$ -lactamases, exhibiting no effect on the class B MBLs due to their use of zinc ions in the hydrolysis reaction (37, 38).

*Extended-Spectrum  $\beta$ -lactamases* – One cause of multi-drug resistant bacteria is due to the emergence of extended-spectrum  $\beta$ -lactamases (ESBLs). Many of these ESBLs are from the Ambler Class A and are derivatives of TEM and SHV type  $\beta$ -lactamases (2, 33). More specifically, ESBLs are classified as oxyimino-cephalosporinases (2, 23), and are able to hydrolyze penicillin as well as cephalosporins such as ceftazidime and cefepime (Table 1). Many of these ESBLs have arisen due to only a few point mutations in either TEM or SHV  $\beta$ -lactamases (2, 39, 40). These point mutations alter the active site of the  $\beta$ -lactamase enough to accept a diverse range of  $\beta$ -lactams. However, they have also been shown to increase their susceptibility to  $\beta$ -lactamase inhibitors such as clavulanate; but of course, additional mutations can make them resistant (2, 38, 41). Figure 4 shows an example of the mutations that lead from TEM-1 to several ESBL TEM variants (2).




FIGURE 3:  $\beta$ -lactamase mediated hydrolysis of a cephalosporin.

A serine residue of the  $\beta$ -lactamase will attack the carbonyl, pushing electrons of the double bond onto the oxygen (Step 1). This leaves a highly unstable negatively charged oxygen. To reduce this strain, the electrons collapse back down, and orbital resonance dissipates the energy across the molecule, opening the  $\beta$ -lactam ring in the process (Step 2). Then, a two-step proton transfer from water to the serine residue of the  $\beta$ -lactamase resolves the hydrolysis reaction (Steps 3-5). [36] (Adapted from original.)




FIGURE 4: ESBL variants of TEM-1.

The common mutations among ESBL variants of TEM-1 are listed. The amino acid numbering is according to the conventions set forth by Ambler. \*TEM-2 is not an ESBL, but several ESBLs are derivatives of TEM-2. \*\*TEM-50 and TEM-68 are resistant to  $\beta$ -lactamase inhibitors. [2]

## Carbapenems and Their Hydrolases

In another effort to avoid the havoc wrought by  $\beta$ -lactamases on the efficacy of these antibiotics, an additional class of  $\beta$ -lactams (carbapenems) was discovered. Because resistance to carbapenems is very infrequent, they are used as a last resort for treating infections to avoid the development of resistance. However, resistance to carbapenems developed anyway. Currently there are about nine diverse types of carbapenemases falling into Ambler Classes A, B, and D (42, 43). Each of those nine types have several variations. We will focus on four clinically relevant types found in *Enterobacteriaceae*, the Class A serine-mediated *Klebsiella pneumoniae* carbapenemase (KPC), and the three Class B metallo- $\beta$ -lactamases (MBL): The New Delhi MBL (NDM), the Verona integron-encoded MBL (VIM), and the Imipenem resistant *Pseudomonas*-type MBL (IMP).

*Klebsiella pneumoniae carbapenemase* – First identified in 2001 (44), KPC was not the first carbapenemase, as several MBLs that could hydrolyze carbapenem had already been identified in Japan in the 1990's (45). This initial variant (KPC-1) provided resistance to many of the  $\beta$ -lactams, including all the cephalosporins and aztreonam, and was also resistant to the  $\beta$ -lactamase inhibitors clavulanic acid and tazobactam (44). A recent review indicates that there are currently 12 reported variants of the KPC enzyme (46). While KPC may not be the first carbapenemase identified, it is the most common in the United States. As of February 27, 2018 the Centers for Disease Control and Prevention (CDC) report that KPC positive infections have been reported from all 50 states and the District of Columbia (47). KPC enzymes have also been reported from many other nations and in numerous gram-negative species, including *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and nearly all the *Enterobacteriaceae* (48-50).

*New-Delhi metallo- $\beta$ -lactamase* – Originally isolated from India in 2008, there are currently more than ten reported variants of NDM (51). It is present in 34 states (47) and multiple countries including the United Kingdom, Pakistan, India, Sweden and others (50). The NDM carbapenemases have shown greater affinities for the penicillins, cephalosporins, and a few of the carbapenems than the VIM and IMP carbapenemases (43). Additionally, a minimum inhibitory concentration assay when NDM is cloned into susceptible strains show it conferring high levels of resistance to penicillins (>256  $\mu\text{g/mL}$ ), cephalosporins (>256  $\mu\text{g/mL}$ ), the monobactam aztreonam (>24  $\mu\text{g/mL}$ ), and all of the carbapenems (>16  $\mu\text{g/mL}$ ) (43), but other reports indicate that NDM cannot hydrolyze aztreonam and, as a MBL, it is resistant to  $\beta$ -lactamase inhibitors (52).

*Verona integron-encoded metallo- $\beta$ -lactamase* – VIM has 14 reported variants with amino acid content varying up to 10% (51). VIM originated from *Pseudomonas aeruginosa* in the Mediterranean in 1997, but quickly spread into *Enterobacteriaceae* and proceeded to spread globally. Reports indicate that VIM can hydrolyze all  $\beta$ -lactams except monobactams and, as an MBL, it is resistant to  $\beta$ -lactamase inhibitors like clavulanate as tazobactam (53). Like the other carbapenemases, plasmids are the primary mechanism for horizontal gene transfer of this carbapenemase. According to the CDC, only 11 states have reported VIM positive infections (47).

*Imipenem resistant Pseudomonas metallo- $\beta$ -lactamase* – IMP shares many of the same characteristics as VIM, but the amino acid content between the two diverges by 70% (51). IMP also represents the most diverse type of carbapenemase with 18 variants reported (51). Isolated in 1991 in Japan from *Pseudomonas*, it is the earliest carbapenemase discovered of the four, and is resistant to the inhibitor clavulanic acid (54). Currently, IMP has been found in many of the

enteric organisms, including *Serratia*, *Providencia*, and *Klebsiella*. As of February 2018, 13 states have reported IMP positive infections (47). As with many of the other carbapenemases, IMP has the ability to hydrolyze many of the  $\beta$ -lactams, but it cannot hydrolyze the monobactams (55).

## Summary

While it is evident that much has been reported on the carbapenemases themselves, there is a distinct lack of published papers characterizing the diversity of plasmids that carry one of these four carbapenemases. Additionally, many of the reviews cited here mention that these carbapenemase-resistance plasmids carry multiple  $\beta$ -lactamases, but the relationship and interplay between the  $\beta$ -lactamases on a single plasmid is not well understood. The following two chapters will clarify these two points.

## CHAPTER 1

### Characterization of Carbapenemase-Resistance Plasmids

Galen E. Card, Brandon D. Pickett, Perry G. Ridge, Richard A. Robison

#### ABSTRACT

Carbapenem-resistant bacteria have quickly become a critical concern in nosocomial infections. In treating these infections, a rapid diagnosis is crucial. Current practices may take up to 76 hours, by which time the infection may become systemic, and the mortality rate is near 50%. To aid in carbapenemase understanding and detection, this report characterizes the gene content and replicon types of 446 carbapenemase-carrying plasmids available in GenBank and identifies the six most prevalent replicon types among these plasmids. The importance of this work is twofold: First, there is no published work that characterizes the plasmids that carry some of the most threatening antibiotic resistance genes, the carbapenemases. Having this information available can aid in knowing where efforts need to be placed to complete our understanding of these plasmids. Second, it highlights challenges that must be overcome if we are to adequately diagnose and restrict the spread of these plasmids.

Key words: Plasmid, Antimicrobial resistance, Carbapenemase, Enterobacteriaceae

#### BACKGROUND

Nosocomial infections have quickly become a significant cause of mortality. In 2002, the US Centers for Disease Control and Prevention estimated that the national mortality rate due to hospital acquired infections was 5.8% (56). In 2011, that rate increased to 10.4% (57). While these same reports show that the chance of acquiring an infection at the hospital has decreased, the infections are becoming more lethal.

One significant reason for this increase in mortality is the acquisition of antibiotic resistance in bacterial populations (25). Bacterial strains such as the carbapenem resistant *Enterobacteriaceae* (CREs), and multi-drug resistant *Pseudomonas aeruginosa* present diagnostic challenges which in turn lead to poor prognoses. Treatment of these bacterial infections usually begins with the administration of standard antibiotic regimens. The ineffectiveness of the initial treatment is usually apparent within 24-48 hours. At this time, the physician needs to reevaluate, order additional antibiotic susceptibility tests, and administer a more advanced antibiotic regimen. This new treatment may include carbapenem antibiotics. For resistant *Enterobacteriaceae* and *Pseudomonas*, this is an additional, ineffective 24-48-hour period before it is apparent that the patient's condition is not improving. At this time, about 76 hours after initial diagnosis, the infection may have become systemic. Once a CRE infection has become systemic, the mortality rate is near 50% (58).

Antibacterial resistance is usually conferred to these organisms through mobile genetic elements, predominately extra-chromosomal DNA called plasmids (25). Plasmids often carry the molecular machinery to replicate themselves. This machinery allows for the transfer of the plasmid between different bacterial strains, and sometimes between any gram-negative bacteria (24). Furthermore, the antibiotic resistance genes on the plasmid can be located within a transposable element. This transposable element has the potential to replicate and integrate itself into new DNA sites, increasing the rate of spread (59). Additionally, many carbapenemase-carrying plasmids are large; therefore, they often carry a toxin/antitoxin plasmid addiction system to prevent the bacterium from losing the plasmid (31).

To assist in the identification and treatment of drug resistant infections, a better understanding of these carbapenemase carrying plasmids is needed. This brief report is the first



large-scale attempt to characterize the diversity of plasmids carrying carbapenemases from the *Klebsiella pneumoniae*-producing carbapenemase (KPC), the New-Delhi metallo- $\beta$ -lactamase (NDM), the Verona-integron encoded metallo- $\beta$ -lactamase (VIM), and the IMP-type metallo- $\beta$ -lactamase (IMP) families in seven clinically-relevant gram-negative bacteria (*Enterobacter aerogenes*, *Enterobacter cloacae*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Providencia stuartii*, and *Serratia marcescens*).

## METHODS

### Sequence acquisition

532 complete plasmid sequences were obtained from GenBank by a discontinuous megablast nucleotide search (60) of four representative carbapenemase genes (IMP, KPC, NDM, VIM, Supplementary File 1) to allow for variations within the carbapenemase family. We employed the same Entrez strategy to filter for complete plasmids as used by Orlek et al. (61):

```
“biomol_genomic[PROP] AND plasmid[filter] NOT complete cds[Title] NOT  
gene[Title] NOT genes[Title] NOT contig[Title] NOT scaffold[Title] NOT whole  
genome map[Title] NOT partial sequence[Title] NOT partial plasmid[Title] NOT  
locus[Title] NOT region[Title] NOT fragment[Title] NOT integron[Title] NOT  
transposon[Title] NOT insertion sequence[Title] NOT insertion element[Title]  
NOT phage[Title] NOT operon[Title]”
```

This blast search was done separately for the seven organisms of interest: *Enterobacter aerogenes*, *Enterobacter cloacae*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Providencia stuartii*, and *Serratia marcescens*. GenBank files were downloaded for each blast alignment that scored >80% identity and query coverage. These sequences were retrieved on 5 March 2018.

### Plasmid gene composition

A list of key terms was derived by a manual survey of 10% of the acquired GenBank files, with cross reference to QuickGO, the European Bioinformatics Institute's Gene Ontology reference database (62), to classify gene products into one of the following categories: (a) Antimicrobial resistance, with  $\beta$ -lactamases as a subset, (b) Plasmid transfer genes, (c) Toxin/antitoxin systems, (d) DNA maintenance, modifying, and repair proteins, (e) Mobile genetic elements, (f) Hypothetical genes, and (g) other. See Appendix A for the list of key terms.

### Incompatibility group/Replicon typing and plasmid characterization

Plasmid incompatibility groups were determined by nucleotide BLAST (60, 63) against a local download of the PlasmidFinder v1.3 *Enterobacteriaceae* database (64) downloaded on 1 March 2018. The incompatibility groups were assigned when matches met the following criteria: (a)  $\geq 80\%$  identity, (b)  $\geq 60\%$  subject coverage, and (c) within 1% of the percent identity of the highest match. Accordingly, more than one incompatibility group could be reported for any given plasmid. Further characterization was accomplished as follows: (a) extracting the CDS regions for each plasmid, (b) searching these CDS regions for key terms using regular expressions, and (c) combining the results for plasmid groups of interest (e.g., those that belong to *Enterobacteriaceae*). Please see Appendix B for a more detailed description. This characterization of each plasmid and of groups of plasmids was accomplished using custom scripts, made freely available at <https://github.com/ridgelab/plasmidCharacterization>.

### Statistical analyses

Since plasmid length distributions are not normal (left-skewed), all statistical analyses were performed with the Mann-Whitney U-test or the Kruskal-Wallis ranked ANOVA where

appropriate, for non-parametric distributions. In an effort to be conservative, statistical significance was determined if  $P < 0.0001$ .

## RESULTS

### Plasmid gene composition

Due to the inherent inconsistencies of GenBank record annotations, our search method required discarding 86/532 accessions, leaving a total of 446 accessions in this analysis (accession numbers available in Appendix C). The criteria for keeping an accession in the analysis was if at least one and no more than six carbapenemase genes were identified on the plasmid. Of those 446 plasmids, 198 carry KPC, 168 carry NDM, 49 carry IMP, and 31 carry VIM. When divided by species, 7 belong to *E. aerogenes*, 33 to *E. cloacae*, 142 to *E. coli*, 235 to *K. pneumoniae*, 18 to *P. aeruginosa*, 3 to *P. stuartii*, and 8 to *S. marcescens*. The mean size of all carbapenemase-carrying plasmids was 104,222 bp, with a median length of 87,663 bp. The largest plasmid was 500,840 bp and the smallest, 1,635 bp. The average percent gene content of all plasmids was as follows: Antimicrobial resistance genes, 8.0%; Plasmid transfer genes, 15.8%; DNA modification genes, 14.7%; Mobile genetic elements, 9.3%; Hypothetical genes, 33.2%; Other/Metabolic genes, 18.9% (Figure 4A). The plasmids carried, on average, ~2  $\beta$ -lactamases, with 22.6% of the plasmids carrying three or more, and the most  $\beta$ -lactamases on a single plasmid being six. The carbapenemase copy number of these plasmids ranged from 1-3, with 97.98% of the plasmids harboring only one carbapenemase.

When comparing certain plasmid features such as the presence or absence of plasmid addiction systems (236/446 or 52.9% of plasmids contain one), polymerase genes, or the family of carbapenemase on the plasmid to plasmid length, the average length of plasmids that carry addiction systems and polymerases are significantly larger than those that do not (Mann-Whitney




FIGURE 5: Characteristics of carbapenemase-encoding plasmids.

A) Mean percent gene content of all plasmids. B) Relationship between characteristics of interest and plasmid length. C) Relationship between species and plasmid length. D) Relationship between incompatibility group and plasmid length, Significance is determined against the average size of all plasmids. B-C) Mann-Whitney U-test, D) Kruskal-Wallis ranked ANOVA. \*\*\*\* P<0.0001. All error bars indicate the 95% CI.

U-test,  $P < 0.0001$ , Figure 4B) and the average length of plasmids that carry KPC are smaller than those that carry IMP (Kruskal-Wallis ranked ANOVA,  $P < 0.05$ , Figure 4B). However, removing an unusually large IMP plasmid ( $> 500$  kb) from this dataset eliminated this significance. When observing average plasmid length by species, the only near-significant difference was observed between *E. coli* and *K. pneumoniae*, with the latter being larger ( $P = 0.0018$ , Figure 4C). It is important to note that these two species also represent most of the plasmids analyzed (377/446 or 84.5%).

#### Plasmid Incompatibility group/Replicon typing

No incompatibility group presented itself as the most abundant; however, the following six groups constitute 80.27% of the plasmids: IncA/C (53/446 or 11.88%), IncFIB (57/446 or 12.78%), IncFII (88/446 or 19.73%), IncN (61/446 or 13.68%), IncR (40/446 or 8.97%), and IncX3 (59/446 or 13.23%) (see Appendix D). Notably, 7.62% (34/446) of the plasmids could not be accurately typed using this method. 58 plasmids carried more than one replicon, and these were significantly larger than those that carried a single replicon (Mann-Whitney U-test  $P < 0.0001$ , data not shown). Additionally, the following incompatibility groups were found to have an average length statistically different (Kruskal-Wallis ranked ANOVA,  $P < 0.0001$ ) than the average of all plasmids: IncA/C2, IncFIB, IncHI1B, and IncX3 (Figure 4D). Figure 5 shows the relative abundance of each incompatibility group among plasmids that carry the same family of carbapenemase (full dataset available, Appendix E).

## DISCUSSION

One of the most notable findings of this study was the amount of hypothetical and uncharacterized genes found on these plasmids. It is possible that many of these genes may be phage derived. This is of great concern when considering phage therapy as an alternative to




FIGURE 6: Relative abundance of incompatibility groups among plasmids. Predominant incompatibility groups from each carbapenemase family: KPC, IncFIB 18.2%, IncFII 20.2%, IncN 17.7%, and IncR 13.6%; NDM, IncA/C2 17.9%, IncFIB 10.7%, IncFII 28.0%, and IncX3 29.2%; IMP, IncA/C2 22.4%, IncL/M 10.2%, IncN 34.7%, and NA 16.3%; VIM, IncA/C2 16.1%, IncN 12.9%, IncR 12.9%, and NA 35.5%. Note: Percent totals are larger than 100% because some plasmids have multiple replicon types.

antibiotics. With potentially large regions of homology to phage genomes, a phage may incorporate into these plasmids through homologous recombination. Then, as the recombinant phage genome is packaged into the progeny phage, it may be possible that carbapenemases could be included, resulting in a replication-deficient phage vector capable of transferring a carbapenemase to a new bacterium through transduction. Before phage therapy of these organisms is seriously pursued, this concept should be investigated so that another mechanism of resistance transfer is not potentiated, as it has been shown for phage and other virulence genes (65).

Additionally, for non-amplification, DNA-based identification of carbapenemase production, it is important to realize that the plasmids of interest are quite large. With their median length over 80 kb, plasmid isolation becomes difficult if necessary for the application, and many of the replicon types identified are for low-copy number plasmids. This also compounds the difficulties when detecting carbapenemase gene presence from a whole-blood specimen, where concentrations are around 10 CFU/mL. This results in approximately 10 copies of an ~800 bp gene that needs to be identified amongst the millions of base pairs in a milliliter of blood.

Finally, this report has identified a few potential targets to slow the spread of carbapenemase plasmids. First, the antitoxin of the plasmid addiction system could be targeted (31). Doing so could prevent its binding with the toxin, resulting in the death of the host harboring the plasmid. Second, 90.4% (403/446) of the plasmids carry transfer genes to pass the plasmid between bacteria. Preventing pilus formation could dramatically reduce the spread of these plasmids. This method is currently being pursued by several groups and include strategies such as bacteriophage, colloidal clays, and antibodies (66). Finally, many of the plasmids carry a

plasmid partitioning system, responsible for ensuring that each daughter receives a copy of the plasmid. Targeting the motor or the partition-site binding protein of these systems, in conjunction with the toxin/antitoxin system, could dramatically reduce the spread and persistence of these plasmids in the hospital. These treatments could be used in a sterilization bath for medical equipment prior to traditional sterilization techniques.

In conclusion, there is an abundance of data for the commonly encountered KPC and NDM carbapenemases from *K. pneumoniae* and *E. coli*, and several non-traditional avenues that may be pursued to help stop the spread of these resistance plasmids. However, this report is lacking data for many of the other species, and for the VIM and IMP carbapenemases. Therefore, a greater surveillance of the other species and carbapenemases is needed. *P. aeruginosa* is a bacterium where much more data is needed to accurately characterize the diversity of carbapenemase-carrying plasmids in this highly significant pathogen.

#### Funding

This work was supported by the U.S. National Institutes of Health (R01 AI116989).

#### Acknowledgements

GEC conceptualized this analysis, determined the functional groups of interest, generated the key terms, and analyzed the output from the scripts. BDP wrote the scripts for the analysis and assisted in writing a portion of the manuscript. PGR and RAR advised this work and reviewed the manuscript. We thank the Fulton Supercomputing Laboratory (<https://marylou.byu.edu>) at Brigham Young University for their consistent efforts to support our research.

#### Conflicts of Interest

The authors have no conflicts of interest to declare.



## CHAPTER 2

### $\beta$ -lactamase Diversity of a Single, Carbapenem-Resistant *Enterobacteriaceae* Isolate

Galen E. Card, Joel S. Griffiths Ph.D., Joshua D. Urquiaga, Richard A. Robison Ph.D.

#### ABSTRACT

Antibiotic resistance is quickly becoming an urgent problem in health care. One class of antibiotics, the  $\beta$ -lactams, has become severely compromised by emerging resistance. Resistance to last-resort  $\beta$ -lactams (the carbapenems) is quickly spreading across the globe. We investigated a carbapenem-resistant isolate of *Klebsiella pneumoniae* possessing six  $\beta$ -lactamase genes: CMY-6, CTX-M-15, NDM-4, OXA-1, SHV-11, and TEM-1. Each of these genes was functionally characterized in *Escherichia coli* using 5  $\beta$ -lactam antibiotics (ampicillin, carbenicillin, ceftazidime, aztreonam, and imipenem). These tests revealed distinct as well as overlapping functions. Most notably, we observed that the carbapenemase NDM-4 provides a greater fitness advantage when grown in a cephalosporin than the cephalosporinase CTX-M-15. Also, we provide evidence that a sizable portion of the resistance that this strain of *Klebsiella* exhibits against aztreonam and imipenem is not enzyme mediated.

#### INTRODUCTION

To date, there are about 20 different derivatives of  $\beta$ -lactam antibiotics approved for therapeutic use. Many of these antibiotics have been put on the World Health Organization's 'WATCH GROUP', due to the higher potential for resistance among bacterial populations [1].  $\beta$ -lactam antibiotics fall into four broad classes; penicillins, cephalosporins, monobactams, and carbapenems, each class representing several clinically important structural derivatives (Fig. 1). With such a wide variety of  $\beta$ -lactams available, most infections can be treated effectively with

these antibiotics. However, the mortality rate from nosocomial infections has been on the rise [2, 3] due to the increased incidence of multi-drug resistant infections [4, 5].

Many genera of the Enterobacteriaceae family have recently joined this class of multi-drug resistant bacteria [6, 7] as they have acquired genes encoding extended-spectrum  $\beta$ -lactamases (ESBL) and carbapenemases (carbapenem resistant Enterobacteriaceae, CRE). Septic infections with ESBL or CRE strains of *Klebsiella pneumoniae* have a mortality rate of near 50% [5].

We have in our collection various CRE isolates possessing 1-6  $\beta$ -lactamase (*bla*) genes. In this work, we characterize one of these isolates (*Klebsiella pneumoniae* strain 1300761), a CRE isolate from which we have identified six distinct *bla* genes: CMY-6, CTX-M-15, NDM-4, OXA-1, SHV-11 and TEM-1. Of these, five belong to the Ambler class A or C, designated as serine mediated hydrolases, with the exception being NDM, which belongs to class B, the metallo- $\beta$ -lactamases which require zinc ions in the active site to catalyze the reaction [8]. Three of them are recognized as ESBLs (CMY-6, CTX-M-15, and NDM-4,) and three are narrow-spectrum  $\beta$ -lactamases (OXA-1, SHV-11, and TEM-1). While hydrolytic activity of these *bla* genes is well documented through MICs, the in vivo fitness advantage provided by them by analyzing growth kinetics is not. In this study, we use a standardized susceptible *E. coli* strain to test resistance conferred by each of these *bla* genes, in response to challenge by five different  $\beta$ -lactam antibiotics. Our observations shed light on the relative contributions of each gene and contribute to our understanding of how multi-gene  $\beta$ -lactamase arsenals may function along with alternative resistance mechanisms to provide strong  $\beta$ -lactam resistance in CRE strains.

## METHODS

Genome sequencing, assembly, and annotation

### *Genome sequencing and read processing*

A carbapenem resistant *Klebsiella pneumoniae* isolate was obtained from the Centers for Disease Control and Prevention (*K. pneumoniae* 1300761) and DNA was extracted following the recommended protocol for the MagNA Pure LC system (Roche Life Sciences). DNA was quantified by fluorometry and 2 $\mu$ g was submitted to the BYU DNA Sequencing Center for 250bp paired end reads on an Illumina HiSeq 2500. Low complexity reads were filtered using PRINSEQ version 0.20.4 [9] and adapter sequence removal and quality trimming was accomplished using Trim Galore! version 0.4.3 with a phred score cutoff of 28. An additional 10bp were trimmed from the 5' end of each read. All reads shorter than 150 bp were then discarded and if their paired read was longer than 150 bp and passed the other quality checks, they were retained as a singleton for use in assembly. Read quality statistics were then assessed using FastQC version 0.11.4 [10].

### *Genome assembly and annotation*

The reads were assembled using the St. Petersburg Assembler (SPAdes) version 3.10.1 [11]. K-mer values of 21, 33, 55, 77, 99, 129 were used for the assembly iterations. Assembly statistics were compiled using QUAST version 4.0 [12]. Gene annotation was undertaken using Prokka version 1.12 [13].

### $\beta$ -lactamase cloning

TABLE 2 contains primer pairs used to introduce restriction sites, a synthetic ribosome binding site, and amplify the corresponding  $\beta$ -lactamases from *K. pneumoniae* 1300761. Each *bla* gene was individually cloned into pJG780 with XbaI/SalI restriction sites (plasmid sequence available in supplemental file 1) and transformed into NEB5-alpha (New England BioLabs), a DH5-alpha derivative, following the manufacturer's provided protocol with a recovery

incubation of 90 minutes. The  $\beta$ -lactamase expression is under the control of a rhamnose-inducible promoter. Each clone was then sequence verified using the following plasmid specific sequencing primer: CTGTCAGTAACGAGAAGGTCG. The resulting strains were named using the following convention: Host vector\_ *bla* (i.e. *E. coli* pJG780\_CMY-6) and are referred to by the  $\beta$ -lactamase they produce (*E. coli* pJG780\_CMY-6 is referred to as CMY-6)

#### Growth curve analysis

A single colony of the  $\beta$ -lactamase clones were grown in 5 ml of LB containing 30  $\mu\text{g}/\text{mL}$  of kanamycin to ensure plasmid retention for 12-18 hours. Then, 100  $\mu\text{L}$  was inoculated in a 5 mL 1-hour subculture containing 30  $\mu\text{g}/\text{mL}$  kanamycin and 0.3% rhamnose to induce  $\beta$ -lactamase expression. Microtiter plates (96-well) were loaded with 190  $\mu\text{L}$  of the selective media (30  $\mu\text{g}/\text{mL}$  kanamycin, 0.3% rhamnose, appropriate  $\beta$ -lactamase) and inoculated with 10  $\mu\text{L}$  of the 1-hour subculture. Preliminary results (data not shown) indicated that the  $\beta$ -lactamase clone growth curves should be performed at the following concentrations: ampicillin (16  $\mu\text{g}/\text{mL}$ ), carbenicillin (16  $\mu\text{g}/\text{mL}$ ), ceftazidime (8  $\mu\text{g}/\text{mL}$ ), aztreonam (8  $\mu\text{g}/\text{mL}$ ), and imipenem (2  $\mu\text{g}/\text{mL}$ ). These concentrations are half of the concentration used to determine antibiotic resistance by the Clinical Laboratory Standards Institute (74). This is relevant since approximately 80  $\mu\text{L}$  of media was lost to evaporation over the course of the growth curve. The plates were then incubated in a BioTek Synergy HT Microplate Reader at 37 °C. OD<sub>600</sub> readings were taken after a brief shaking every 30 minutes over a 10.5-hour growth period. The growth curves were also performed on the parent strain (*K. pneumoniae* 1300761) in LB with the previously indicated antibiotics. Each growth curve was measured in duplicate, and the experiment was repeated three times.

TABLE 2: PCR primers for the cloning of  $\beta$ -lactamase genes found in *Klebsiella pneumoniae* 1300761.

<i>bla</i> gene	Forward Primer	Reverse Primer
CMY-6	cagctctagaggagGATTTTCATGATGA AAAAATCGTTATGCTGC	cagcgtcgacGCCTCATCGTCAGTT ATTGCAGC
CTX-M-15	cagctctagaggaggAATCCCATGGTT AAAAAATCACTGC	cagcgtcgaCGCTATTACAAACCGT CGGTG
NDM-4	cagctctagaggaggAACTTGATGGAA TTGCCCAATATTATG	cagcgtcgacGTCAGCCATGGCTCA GCGC
OXA-1	cagctctagaggaggCTTATTATGAAA AACACAATACATATCAACTTCGC	cagcgtcgacGGGTTGGGCGATTTT GCCATTAG
SHV-11	cagctctagaggagGTGGTTATGCGTT ATATTCGCCTGTGT	cagcgtcgacGGGTTAGCGTTGCCA G
TEM-1	cagctctagaggaggAAGAGTATGAGT ATTCAACATTTTCGTGTC	cagcgtcgacTTGGTCTGACAGTTA CCAATGCTTAATC
Restriction site <u>Ribosome binding site</u>		

## Statistical analysis

A two-way ANOVA in conjunction with Fisher's Least Significant Difference test was used to compare all time points against the control. Significance was determined if  $P < 0.05$ . When a  $\beta$ -lactamase clone reached absorbance levels significantly different than the control before another in the same antibiotic, it was determined that the clone that reached significant absorbance levels first is more efficient at hydrolyzing that  $\beta$ -lactam. When comparing growth curves of a single  $\beta$ -lactamase in different growth conditions, if the growth curve in one antibiotic reached significant absorbance levels at an earlier time point than another, it was determined that that  $\beta$ -lactamase was more efficient at hydrolyzing the  $\beta$ -lactam that allowed quicker growth.

## RESULTS

*Klebsiella pneumoniae* 1300761 possesses six  $\beta$ -lactamase-encoding genes

Illumina sequencing produced 3,653,470 paired reads, and read processing reduced that number to 3,370,288 with 80,534 retained as singletons, for approximately 150X coverage of the genome. The average quality score of all reads is greater than 37, with an average length of 215. Assembly generated 196 contigs larger than 1,000 bp, with an N50 of 238,732 and N75 of 112,412. The genome length is 5,972,622 bp. Annotation predicted 5,733 genes. Notably, 6 distinct *bla* genes were detected (Supplemental File 2) and confirmed by BLAST search [15] as the following; *bla*<sub>CMY-6</sub>, *bla*<sub>CTX-M-15</sub>, *bla*<sub>NDM-4</sub>, *bla*<sub>OXA-1</sub>, *bla*<sub>SHV-11</sub>, and *bla*<sub>TEM-1</sub>. These *bla* genes were then cloned into NEB5- $\alpha$  for further characterization.

### Resistance profiles of $\beta$ -lactamase clones

The control group in these Figs 2A-F is the pJG780 empty vector. When grown in nutrient rich, non-selective LB, the only significant results were CTX-M-15, NDM-4 and OXA-

1; which had a significantly lower carrying capacity at 630 minutes (Fig 2A). When growth occurred in LB ampicillin, all  $\beta$ -lactamases except CMY-6 reached growth levels significantly different than the control by 300 minutes and by 630 minutes, CMY-6 also reached significant levels (Fig 2B). In LB carbenicillin, all  $\beta$ -lactamases were at significant levels by 300 minutes, and CMY-6 after 630 minutes (Fig 2C). In LB ceftazidime, NDM growth was evident by 300 minutes and CTX-M-15 by 630 minutes (Fig 2D). CTX-M-15 was the only  $\beta$ -lactamase that hydrolyzed aztreonam, and significant levels were reached by 630 minutes (Fig 2E). NDM-4 was the only  $\beta$ -lactamase that hydrolyzed imipenem, with growth observed by 300 minutes, but not reaching significant levels until 630 minutes (Fig 2F). Complete growth curves are reported in Fig S1, raw data in Table S1.

#### $\beta$ -lactam preferences for a single $\beta$ -lactamase

In these comparisons, the growth curve for pJG780 grown in ampicillin was used as a negative control (Figs 3A-G). As expected, pJG780 only grew in LB, and attained growth levels significantly different from the negative control by 300 minutes (Fig 3A). CMY-6 was able to grow in ampicillin, and carbenicillin, however, this clone grew slowly in ampicillin, reaching growth levels different than the control by 630 minutes (Fig 3B). CTX-M-15 grew in all antibiotics except imipenem and growth was observed in ceftazidime by 630 minutes, but not yet above background levels. By 300 minutes growth was evident in ampicillin and carbenicillin and by 630 minutes for aztreonam (Fig 3C). NDM-4 grew in all antibiotics, except aztreonam. Ampicillin, carbenicillin and ceftazidime reached significance by 300 minutes and imipenem by 630 minutes. (Fig 3D). OXA-1, SHV-11, and TEM-1 only grew in ampicillin and carbenicillin, reaching significant levels in each case by 300 minutes (Fig 3E-H). Complete growth curves can be found in Fig S2, raw data in Table S1.




FIGURE 7: Growth curves grouped by growth conditions. A) Nonrestrictive LB broth. B) Ampicillin. C) Carbenicillin. D) Ceftazidime. E) Aztreonam. F) Imipenem. \* $P < 0.05$  \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .






FIGURE 8: Growth curves of the  $\beta$ -lactamase clones.

The clones were grown for 630 minutes, and the OD600 was measured every 30 minutes. A) The pJG780 empty vector control strain. B) The CMY-6 clone. C) The CTX-M-15 clone. D) The NDM-4 clone. E) The OXA-1 clone. F) The SHV-11 clone. G) The TEM-1 clone. H) The parent strain *K. pneumoniae* 1300761. \*P<0.05 \*\*P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.

Growth of the parent strain *K. pneumoniae* 1300761 is not inhibited by any  $\beta$ -lactam tested

The two-way ANOVA indicated that antibiotic has no significant impact on growth, even though individual time points may have randomly showed significance from the LB control (i.e. imipenem at 630 minutes) (Fig 3H). Additionally, the lack of a significant lag phase when this isolate was introduced to antibiotic-containing media, indicated that these genes are constitutively expressed in *K. pneumoniae* 1300761.

## DISCUSSION

The antibiotic crisis is reaching a crescendo as nosocomial bacteria acquire resistance to the common, and last resort, antibiotics. Furthermore, it appears that individually, these *bla* genes may not pose a large threat, as the fitness provided is relatively weak (i.e. imipenem, ceftazidime, aztreonam). But there appears to be a synergistic effect as they are combined, and that the additional resistance factors *Klebsiella* possesses (truncated porins, multi-drug efflux pumps) aid greatly in its resistance. At the concentrations assayed, it seems that NDM-4 is superior to CTX-M-15 as a cephalosporinase. Interestingly, it also appears that the cephalosporinase CTX-M-15 provides a greater fitness advantage to aztreonam (a monobactam) than ceftazidime (a cephalosporin). Finally, CMY-6 provides a better degree of fitness when grown in ampicillin than carbenicillin. *Tblahis* result is interesting, and several *bla*<sub>CMY</sub> genes have been shown to hydrolyze cephalosporins at aztreonam at high concentrations (76, 77). Another path that could shed greater light on fitness provided by these various  $\beta$ -lactamases would be to perform competition assays between them in the various antibiotics. Additionally, this strategy could also help characterize the differences between the various carbapenemases.

In conclusion, this study helps us understand that these organisms may acquire redundant genes for the synergism acquired. This synergism provides the parent strain enhanced fitness in antibiotics such as aztreonam and imipenem, where only one of the antibiotics hydrolyzes it, but the parent strain grows normally. Additionally, this disparity in growth curve statistics may also indicate that the passive resistance mechanisms (i.e. efflux pumps, altered porins) play a more substantial role in resistance than previously thought, and they should receive more concentrated attention.

#### ACKNOWLEDGEMENTS

GEC was responsible for designing and performing experiments, assembling and annotating the genome, and drawing conclusions and he is the primary author of this manuscript. JSG helped design the molecular cloning methodology and assisted in the molecular cloning work. JDU helped perform experiments. RAR secured funding, and experiments were performed in his laboratory. We would like to express our thanks to the BYU Fulton Supercomputing Laboratory (<https://marylou.byu.edu>), the BYU Research Instrumentation Core (<https://ricfacility.byu.edu>), and the BYU DNA Sequencing Center (<https://dnasc.byu.edu>) for their consistent efforts to support our research. This work was funded by the U.S. National Institutes of Health (R01 AI116989). The authors have no conflicts of interest to declare.

## SUMMARY

This thesis provides only a starting point for further investigation. Much is still needed to fully characterize these plasmids, and a greater surveillance of carbapenem-resistance plasmids is needed to create a more comprehensive picture. Furthermore, several points are identified in chapter 1 that can be exploited by small molecule inhibition to limit or eliminate the spread of these plasmids. Additionally, there is a wealth of data available for the *Escherichia coli* and *Klebsiella pneumoniae* carbapenem resistant isolates. This data could be mined for numerous points of interest and conclusions made.

Second, the assay set up in chapter two could be used to assess the level of fitness provided by the various carbapenemases. Additionally, as mention in chapter 2, competition assays between these strains would also help determine if a fitness advantage is provided by the  $\beta$ -lactamase activity, or if metabolic costs of producing the  $\beta$ -lactamase are a detriment to fitness.

## REFERENCES

1. Iredell J, Brown J, Tagg K. 2016. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. *Bmj-British Medical Journal* 352:19.
2. Bradford PA. 2001. Extended-Spectrum  $\beta$ -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clinical Microbiology Reviews* 14:933-951.
3. Sonnevend A, Ghazawi A, Hashmey R, Haidermota A, Girgis S, Alfaresi M, Omar M, Paterson DL, Zowawi HM, Pal T. 2017. Multihospital Occurrence of Pan-Resistant *Klebsiella pneumoniae* Sequence Type 147 with an ISEcp1-Directed bla(OXA-181) Insertion in the mgrB Gene in the United Arab Emirates. *Antimicrobial Agents and Chemotherapy* 61:9.
4. Borer A, Saidel-Odes L, Riesenberk K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. 2009. Attributable Mortality Rate for Carbapenem-Resistant *Klebsiella pneumoniae* Bacteremia. *Infection Control and Hospital Epidemiology* 30:972-976.
5. WHO/FAO. 2015. Codex texts on foodborne antimicrobial resistance. World Health Organization/Food and Agriculture Organization of the United Nations, Rome, Italy.
6. Hudson JA, Frewer LJ, Jones G, Brereton PA, Whittingham MJ, Stewart G. 2017. The agri-food chain and antimicrobial resistance: A review. *Trends in Food Science & Technology* 69:131-147.
7. Dunlop RH, McEwen SA, Meek AH, Clarke RC, Black WD, Friendship RM. 1998. Associations among antimicrobial drug treatments and antimicrobial resistance of fecal *Escherichia coli* of swine on 34 farrow-to-finish farms in Ontario, Canada. *Preventive Veterinary Medicine* 34:283-305.

8. Agersø Y, Sandvang D. 2005. Class 1 Integrons and Tetracycline Resistance Genes in *Alcaligenes*, *Arthrobacter*, and *Pseudomonas* spp. Isolated from Pigsties and Manured Soil. *Applied and Environmental Microbiology* 71:7941-7947.
9. Zhang X-X, Zhang T, Fang HHP. 2009. Antibiotic resistance genes in water environment. *Applied Microbiology and Biotechnology* 82:397-414.
10. Keen PL, Knapp CW, Hall KJ, Graham DW. 2018. Seasonal dynamics of tetracycline resistance gene transport in the Sumas River agricultural watershed of British Columbia, Canada. *Science of the Total Environment* 628-629:490-498.
11. Aarestrup FM. 1999. Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistant bacteria among food animals. *International Journal of Antimicrobial Agents* 12:279-285.
12. Wegener HC. 2003. Antibiotics in animal feed and their role in resistance development. *Current Opinion in Microbiology* 6:439-445.
13. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161-8.
14. Willems RJL, Top J, Braak van den N, van Belkum A, Endtz H, Mevius D, Stobberingh E, van den Bogaard A, van Embden JDA. 2000. Host Specificity of Vancomycin-Resistant *Enterococcus faecium*. *The Journal of Infectious Diseases* 182:816-823.
15. Bruinsma N, Willems RJL, van den Bogaard AE, van Santen-Verheувel M, London N, Driessen C, Stobberingh EE. 2002. Different Levels of Genetic Homogeneity in

- Vancomycin-Resistant and -Susceptible *Enterococcus faecium* Isolates from Different Human and Animal Sources Analyzed by Amplified-Fragment Length Polymorphism. *Antimicrobial Agents and Chemotherapy* 46:2779-2783.
16. Angulo FJ, Nargund VN, Chiller TC. 2004. Evidence of an Association Between Use of Anti- microbial Agents in Food Animals and Anti- microbial Resistance Among Bacteria Isolated from Humans and the Human Health Consequences of Such Resistance. *Journal of Veterinary Medicine, Series B* 51:374-379.
  17. Poulsen MN, Pollak J, Sills DL, Casey JA, Rasmussen SG, Nachman KE, Cosgrove SE, Stewart D, Schwartz BS. 2018. Residential proximity to high-density poultry operations associated with campylobacteriosis and infectious diarrhea. *International Journal of Hygiene and Environmental Health* 221:323-333.
  18. Livermore DM. 1995. Beta-lactamases in laboratory and clinical resistance. *Clinical Microbiology Reviews* 8:557.
  19. Ellner PD, Fink DJ, Neu HC, Parry MF. 1987. Epidemiologic factors affecting antimicrobial resistance of common bacterial isolates. *Journal of Clinical Microbiology* 25:1668-1674.
  20. Sanders CC, Sanders WE. 1992. Beta-lactamase resistance in gram-negative bacteria - global trends and clinical impact. *Clinical Infectious Diseases* 15:824-839.
  21. WHO. 2017. Does stopping a course of antibiotics early lead to antibiotic resistance?, *on* World Health Organization. <http://www.who.int/features/qa/stopping-antibiotic-treatment/en/>. Accessed 1/29/2018.
  22. Weaver RF. 2012. *Molecular Biology*, 5th ed. McGraw-Hill, New York City, NY.

23. Bush K, Jacoby GA, Medeiros AA. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrobial Agents and Chemotherapy* 39:1211-1233.
24. Logan LK, Weinstein RA. 2017. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. *The Journal of Infectious Diseases* 215:S28-S36.
25. Read AF, Woods RJ. 2014. Antibiotic resistance management. *Evolution, Medicine, and Public Health* 2014:147.
26. Lauritsen I, Kim SH, Porse A, Nørholm MH. 2018. Standardized Cloning and Curing of Plasmids, p 469-476, *Synthetic Biology*. Springer.
27. Zhou Y. 2018. Plasmid Curing in *Yersinia pestis*, p 173-182, *Yersinia Pestis Protocols*. Springer.
28. Onifade AK, Palmer OG. 2018. Plasmid Profile Analysis and Curing of Multidrug-Resistant Bacteria Isolated from Hospital Environmental Surfaces in Akure Metropolis, Ondo State, Nigeria. *American Journal of Information Science and Technology* 2:18-23.
29. Fernández-García L, Blasco L, Lopez M, Bou G, García-Contreras R, Wood T, Tomas M. 2016. Toxin-Antitoxin Systems in Clinical Pathogens. *Toxins* 8:227.
30. Engelberg-Kulka H, Glaser G. 1999. Addiction modules and programmed cell death and antideath in bacterial cultures. *Annu Rev Microbiol* 53:43-70.
31. Tsang J. 2017. Bacterial plasmid addiction systems and their implications for antibiotic drug development. *Postdoc journal : a journal of postdoctoral research and postdoctoral affairs* 5:3-9.



32. Hayes F. 2003. Toxins-Antitoxins: Plasmid Maintenance, Programmed Cell Death, and Cell Cycle Arrest. *Science* 301:1496-1499.
33. Ambler RP. 1980. The structure of beta-lactamases. *Philos Trans R Soc Lond B Biol Sci* 289:321-31.
34. Medeiros A, Mayer KH, Opal SM. 1988. Plasmid-mediated beta-lactamases. *Antimicrobial Newsletter* 5:61-65.
35. Bonomo RA, Tolmasky ME. 2007. *Enzyme-Mediated Resistance to Antibiotics : Mechanisms, Dissemination, and Prospects for Inhibition*. ASM Press, Washington, United States.
36. Tomanicek SJ, Wang KK, Weiss KL, Blakeley MP, Cooper J, Chen Y, Coates L. 2011. The active site protonation states of perdeuterated Toho-1  $\beta$ -lactamase determined by neutron diffraction support a role for Glu166 as the general base in acylation. *FEBS Letters* 585:364-368.
37. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-beta-lactamases: the quiet before the storm? *Clin Microbiol Rev* 18:306-25.
38. Drawz SM, Bonomo RA. 2010. Three Decades of  $\beta$ -Lactamase Inhibitors. *Clinical Microbiology Reviews* 23:160-201.
39. Sougakoff W, Goussard S, Courvalin P. 1988. The TEM-3 beta-lactamase, which hydrolyzes broad-spectrum cephalosporins, is derived from the TEM-2 penicillinase by 2 amino-acid substitutions. *Fems Microbiology Letters* 56:343-348.
40. Sougakoff W, Goussard S, Gerbaud G, Courvalin P. 1988. Plasmid-mediated resistance to 3rd-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. *Reviews of Infectious Diseases* 10:879-884.

41. Jacoby GA, Sutton L. 1991. Properties of plasmids responsible for production of extended-spectrum beta-lactamases. *Antimicrobial Agents and Chemotherapy* 35:164-169.
42. Overturf GD. 2010. Carbapenemases: A Brief Review for Pediatric Infectious Disease Specialists. *The Pediatric Infectious Disease Journal* 29:68-70.
43. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a New Metallo- $\beta$ -Lactamase Gene, bla(NDM-1), and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in *Klebsiella pneumoniae* Sequence Type 14 from India. *Antimicrobial Agents and Chemotherapy* 53:5046-5054.
44. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. 2001. Novel Carbapenem-Hydrolyzing  $\beta$ -Lactamase, KPC-1, from a Carbapenem-Resistant Strain of *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy* 45:1151-1161.
45. Paterson DL, Bonomo RA. 2005. Extended-Spectrum  $\beta$ -Lactamases: a Clinical Update. *Clinical Microbiology Reviews* 18:657-686.
46. Sotgiu G, Are BM, Pesapane L, Palmieri A, Muresu N, Cossu A, Dettori M, Azara A, Mura II, Cocuzza C, Aliberti S, Piana A. 2018. Nosocomial transmission of carbapenem-resistant *Klebsiella pneumoniae* in an Italian university hospital: a molecular epidemiological study. *Journal of Hospital Infection*  
doi:<https://doi.org/10.1016/j.jhin.2018.03.033>.

47. Anonymous. Feb 27, 2018. Tracking CRE, *on* Centers for Disease Control and Prevention. <https://www.cdc.gov/hai/organisms/cre/trackingcre.html>. Accessed June 08, 2018.
48. Arnold RS, Thom KA, Sharma S, Phillips M, Johnson JK, Morgan DJ. 2011. Emergence of *Klebsiella pneumoniae* Carbapenemase (KPC)-Producing Bacteria. *Southern medical journal* 104:40-45.
49. Codjoe FS, Donkor ES. 2018. Carbapenem Resistance: A Review. *Medical Sciences* 6:1.
50. Perez F, Van Duin D. 2013. Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients. *Cleveland Clinic journal of medicine* 80:225-233.
51. Bedenić B, Plečko V, Sardelić S, Uzunović S, Godič Torkar K. 2014. Carbapenemases in Gram-Negative Bacteria: Laboratory Detection and Clinical Significance. *BioMed Research International* 2014:841951.
52. Shakil S, Azhar EI, Tabrez S, Kamal MA, Jabir NR, Abuzenadah AM, Damanhoury GA, Alam Q. 2011. New Delhi Metallo-beta-Lactamase (NDM-1): An Update. *Journal of Chemotherapy* 23:263-265.
53. Marsik FJ, Nambiar S. 2011. Review of carbapenemases and AmpC-beta lactamases. *Pediatr Infect Dis J* 30:1094-5.
54. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. 1991. Transferable imipenem resistance in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* 35:147-151.
55. Laraki N, Franceschini N, Rossolini GM, Santucci P, Meunier C, de Pauw E, Amicosante G, Frère JM, Galleni M. 1999. Biochemical Characterization of the *Pseudomonas aeruginosa* 101/1477 Metallo-β-Lactamase IMP-1 Produced by *Escherichia coli*. *Antimicrobial Agents and Chemotherapy* 43:902-906.

56. Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM. 2007. Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002. *Public Health Reports* 122:160-166.
57. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. 2014. Multistate Point-Prevalence Survey of Health Care-Associated Infections. *New England Journal of Medicine* 370:1198-1208.
58. Gross M. 2013. Antibiotics in crisis. *Current Biology* 23:R1063-R1065.
59. Cuzon G, Naas T, Nordmann P. 2011. Functional Characterization of Tn4401, a Tn3-Based Transposon Involved in bla(KPC) Gene Mobilization. *Antimicrobial Agents and Chemotherapy* 55:5370-5373.
60. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic Local Alignment Search Tool. *Journal of Molecular Biology* 215:403-410.
61. Orlek A, Phan H, Sheppard AE, Doumith M, Ellington M, Peto T, Crook D, Walker AS, Woodford N, Anjum MF, Stoesser N. 2017. Ordering the mob: Insights into replicon and MOB typing schemes from analysis of a curated dataset of publicly available plasmids. *Plasmid* 91:42-52.
62. Anonymous. QuickGO: Gene Ontology and GO Annotations, on EMBL-EBI. <https://www.ebi.ac.uk/QuickGO/>. Accessed 03/05/18.
63. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. *BMC Bioinformatics* 10:421.
64. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen M, Lund O, Villa L, Moller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using

- PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895-903.
65. Moon BY, Park JY, Robinson DA, Thomas JC, Park YH, Thornton JA, Seo KS. 2016. Mobilization of Genomic Islands of *Staphylococcus aureus* by Temperate Bacteriophage. *Plos One* 11:16.
  66. Getino M, de la Cruz F. 2018. Natural and Artificial Strategies To Control the Conjugative Transmission of Plasmids. *Microbiology Spectrum* 6.
  67. WHO. 2017. WHO Model List of Essential Medicines. World Health Organization,
  68. de Lencastre H, Oliveira D, Tomasz A. 2007. Antibiotic resistant *Staphylococcus aureus*: a paradigm of adaptive power. *Current opinion in microbiology* 10:428-435.
  69. Schmieder R, Edwards R. 2011. Quality control and preprocessing of metagenomic datasets. *Bioinformatics* 27:863-4.
  70. Andrews S. 2017. FastQC: a quality control tool for high throughput sequence data. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>. Accessed
  71. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing. *Journal of Computational Biology* 19:455-477.
  72. Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUAST: quality assessment tool for genome assemblies. *Bioinformatics* 29:1072-1075.
  73. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068-9.

74. CLSI. 2016. Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. Clinical Laboratory Standards Institute, Wayne, Pennsylvania.
75. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J Mol Biol* 215:403-10.
76. Bauernfeind A, Stemplinger I, Jungwirth R, Giamarellou H. 1996. Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance. *Antimicrobial Agents and Chemotherapy* 40:221-224.
77. Bauernfeind A, Stemplinger I, Jungwirth R, Wilhelm R, Chong Y. 1996. Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes. *Antimicrobial Agents and Chemotherapy* 40:1926-1930.

## APPENDIX A

TABLE 3: Key Words used to characterize CR-plasmid gene content.

Categories	Key Word	Python Regular Expression
Antimicrobial Resistance	aac	aac
	aad	aad
	aminoglyco*	aminoglyco[^\s]
	aph	aph
	arr-	arr-
	arsa	ars[a-dhr]
	arsb	"
	arsc	"
	arsd	"
	arsh	"
	arsr	"
	arsen*	arsen[^\s]
	bleomycin	bleomycin
	catr	catr
	chloramphenicol	chloramphenicol
	cmea	cme[abc]
	cmeb	"
cmec	"	

copper	copper
dfra	(?:[ <sup>^</sup> a-z]  <sup>^</sup> )dfra(?:\$ [ <sup>^</sup> a-z])
efflux pump	efflux pump
flor	flor
fluoroquino*	fluoroquino[ <sup>^</sup> s]
folp	(?:[ <sup>^</sup> a-z]  <sup>^</sup> )folp(?:\$ [ <sup>^</sup> a-z])
macrolide	macrolide
mercur*	mercur[ <sup>^</sup> s]
mph	mph
multidrug	multidrug
nkra	(?:[ <sup>^</sup> a-z]  <sup>^</sup> )nkr[a-c,y](?:\$ [ <sup>^</sup> a-z])
ncrb	"
ncrc	"
ncry	"
nickel resistant	(?:sulfonamide trimethoprim nickel)[ <sup>-</sup> ]resistant
nirb	(?:[ <sup>^</sup> a-z]  <sup>^</sup> )nirb(?:\$ [ <sup>^</sup> a-z])
sulfonamide resistant	"
trimethoprim resistant	"
pcoa	pco[a-ers]
pcob	"



pcoc	"
pcod	"
pcoe	"
pcor	"
pcos	"
qace	qace
resistance	resistance
rifampin	rifamp(?:in icin)
sil	sil[abcefprs]
silb	"
silc	"
sile	"
silf	"
silp	"
silr	"
sils	"
silver	silver
streptomycin	streptomycin
sul	(?:[^\a-z] ^sul[12](?:\$  [^\a-z])
teller*	teller[^\s]

Antimicrobial Resistance, Beta-lactamase

tera	ter[abcfw-z](?:\$ ^[^a-z])
terb	"
terc	"
terf	"
terw	"
terx	"
tery	"
terz	"
tetr	tetr(?:\$ ^[^a])acycline)

---

ampr	(?:^[^p])ampr
beta lactam*	beta[-]lactam[^s]
beta-lactam*	"
bla	(?:^[^p])bla
cephalosporin*	cephalosporin[^s]
cmy-	(?:^[^p])cmy-
ctx-	(?:^[^p])ctx-
dha-	(?:^[^p])dha-
oxa-	(?:^[^p])oxa-
oxacillin*	oxacillin[^s]
penicillin*	penicillin[^s]

---

	sfo-	(?:^[^p])sfo-
	shv-	(?:^[^p])shv-
	tem-	(?:^[^p])tem-
Antimicrobial Resistance, Beta-lactamase, Beta-lactamase Special	carbapenem*	carbapenem[^\s]
	imp not (impa or impb or impc)	(?:^[^b-z])imp(?:\$ ^[^abc])
	kpc	(?:^[^b-z])kpc
	ndm	(?:^[^b-z])ndm
	vim	(?:^[^b-z])vim
Plasmid Transfer	conjuga*	conjuga[^\s]
	fertility inhibition	fertility inhibition
	fino	fino
	icm*	icm[^\s]
	moba	mob[a-e]
	mobb	"
	mobc	"
	mobd	"
	mobe	"
	pili*	pili[^\s]
	pilus	pilus
	pilx	pilx

secretion system

secretion system

tivb\*

tivb[^\s]

traa

tra[a-rtuwxy](?:\$|^[^a-z])

trab

"

trac

"

trad

"

trae

"

traf

"

trag

"

trah

"

trai

"

traj

"

trak

"

tral

"

tram

"

tran

"

trao

"

trap

"

traq

"

trar

"

---

	trat	"
	trau	"
	traw	"
	trax	"
	tray	"
	trba	trb[a-gilm]
	trbb	"
	trbc	"
	trbe	"
	trbf	"
	trbg	"
	trbi	"
	trbl	"
	trbm	"
	type iv	type[-]iv
	type-iv	"
	vir* not virulence	vir[^ugo\s]
Toxin/Antitoxin System	abrb	abrb
	cbta	cbta
	ccda	ccd[ab]

ccdb	"
hica	hica
higa	hig[ab]
higb	"
hokg	hokg
pard	par[de]
pare	"
pemi	pem[ik]
pemk	"
relb	rel[be]
rele	"
stbd	stb[de]
stbe	"
toxi*	(?:^[^a-z] anti)toxi[^\s]
yafo	yafo

---

DNA  
Maintenance/Modification

---

chromosome	chromosome
dna	dna
eex	eex
entry exclusion	entry exclusion
exca	exca

helicase	helicase
integrase	integrase
kfra	kfra
kora	kor[ab]
korb	"
methylase	methylase
nucleoti*	nucleoti[^\s]
para	par[ab]
parb	"
plasmid	plasmid
recombinase (not serine or tyrosine recombinase)	(?!ser_ ine )recombinase
relaxase	relaxase
repa	repa
replication	replication
replication protein	replication protein
ruma	ruma
single-strand binding protein	single-strand binding protein
ssb	ssb
topb	topb
topoisomerase	topoisomerase

---

	trfa	trfa
	uvr*	uvr[^\s]
	vagc	vag[cd]
	vagd	"
DNA Maintenance/Modification, DNA Maintenance/Modification Special	muca	muc[ab]
	mucb	"
	polymerase	polymerase
	umuc	umu[cd]
	umud	"
Mobile Genetic Elements	ista	ist[ab](?:\$ [\^a-z0-9])
	istb	"
	resolvase	resolvase
	reverse transcriptase	reverse transcriptase
	tnp	tnp
	transpos*	transpos[^\s]
	urf2	urf2
Hypothetical Genes	domain containing	domain[-]containing
	domain-containing	"
	hypothetical	hypothetical
	uncharacterized protein	uncharacterized protein



	unknown function	unknown function
Ignored	disrupted	disrupted
	imperfect	imperfect
	interrupted	interrupted
	intron	intron
	is(?:[a-z]{2} )[0-9]{2,4}	is(?:[a-z]{2} )[0-9]{2,4}
	kl.pn.i3	kl\.pn\.i3
	morpho	morpho
	ncrna	ncrna
	non functional	non[-]?functional
	non-functional	"
	partial	partial
	patho	patho
	repeat region	repeat region
	se.ma.*	se\.ma\.[\s]
	truncated	truncated

## APPENDIX B

### Supplementary Bioinformatics Methods

This is a more detailed explanation of the bioinformatics methods required for incompatibility group/replicon typing and plasmid characterization. This will describe a step-by-step walkthrough of the process. Please note that most of these steps will be simple data formatting. Also note that it would have been easier in some cases to combine multiple steps into one. The choice to separate each piece of the process was for clarity and to enable another to modify this process for their own purposes. For our work, all steps could be run interactively; i.e., not requiring a high-performance computing (HPC) architecture. Our work was completed on a machine running Red Hat Enterprise Linux.

#### Summary

This process begins with one fasta file and multiple GenBank files. The formats for these files are described in steps 0 and 2, respectively. The fasta file contains the incompatibility group sequences. In our work, this was a download of the PlasmidFinder v1.3 *Enterobacteriaceae* database (64). The GenBank files contain one or more GenBank records in them, where each record could itself be considered a GenBank file for a single accession number. Thus, these GenBank files are concatenations of multiple GenBank records. Effectively, this is how we grouped accessions of interest. The same accession may appear in multiple groupings. Note, if you attempt to re-use our process with your own data and have GenBank files as a single file per accession, combining them into groups will feel unnecessary. We began this way because that is what we had to start with.

The results of the entire process are CSV files with information about each plasmid in a group and a text file with summary statistics about each group. The file contains basic

information (e.g., plasmid length), the incompatibility group(s) the plasmid best aligns to, and some gene/function annotation based on key term searches of the GenBank file's CDS regions. To accomplish this, each (input) group GenBank file is split into a single GenBank file per accession and the sequences are extracted as fasta files. The sequence lengths are recorded and these sequences are individually aligned (using the NCBI BLAST+ Suite (60, 63)) to the incompatibility group sequences. After filtering out the "best" alignments, the incompatibility group is determined and saved for later assimilation into the final outputs. The CDS regions are extracted from the GenBank files and searched for key terms using regular expressions. Each key term belongs to one or more categories. Matches in each category are counted and summarized in the final output. For more details on this searching strategy, please see step #11. The key terms are listed with their Python regular expression in Appendix A.

This summary concludes with an outline of the steps. Each step will be detailed, followed by the references. The code in the detailed steps has, in many cases, been simplified. In other cases, the code is several pages long and would be difficult to copy and paste effectively. Especially the with Python code, readability suffers as lines wrap because a standard page is not wide enough to contain some code statements on a single line. Accordingly, we encourage you to visit the online repository for the code: <https://github.com/ridgelab/plasmidCharacterization>.

### Outline of Steps

Step 0. Format Incompatibility Groups Fasta File

Step 1. Create Incompatibility Groups BLAST database

Step 2. Split Multi-Accession GenBank Files

Step 3. Extract ORIGIN Sequence from GB to Fasta

Step 4. Extract Group Lists

Step 5. Blast Incompatibility Groups

Step 6. Subset BLAST Results by Coverage Cutoff of 60%

Step 7. Add Incompatibility Group Family as Column to BLAST Results

Step 8. Filter Best Matches in BLAST Results

Step 9. Extract Incompatibility Families

Step 10. Extract Plasmid Search Regions

Step 11. Identify Plasmid Matches

Step 12. Generate Plasmid CSVs

Step 13. Create CSVs from Plasmid CSVs

Step 14. Create Group Matches from Plasmid Matches

Step 15. Calculate Group Statistics from Group CSV

Step 0. Format Incompatibility Groups Fasta File

Input: Fasta file with incompatibility group sequences. Each sequence may be on one or more lines. The headers might start with “Inc”.

Output: Same fasta file as the input, but sequences occur on only one line. Headers without “Inc” now have “Inc” prepended.

Code:

Bash Command

```
awk -f formatIncGroupFasta.awk \  
    original_incomp-grp.fasta \  
    > incomp-grp.fasta
```

AWK Script (formatIncGroupFasta.awk)

```
#!/bin/awk -f  
  
{  
    if ( $0 ~ /^>.+$/ ) {
```

```

        if ( NR != 1 ) {
            printf "\n";
        }

        if ( $0 ~ /^>Inc.+$/ ) {
            print $0;
        }
        else {
            printf "%s%s\n", ">Inc", substr($0, 2);
        }
    }
    else {
        printf "%s", $0;
    }
}

END {
    printf "\n";
}

```

### Step 1. Create Incompatibility Groups BLAST database

Input: Fasta file with incompatibility group sequences. Each sequence is on only one line.

The headers start with “>Inc”.

Output: BLAST database of the incompatibility group sequences.

Code:

#### Bash Command

```

makeblastdb \
    -dbtype nucl \
    -in incompatibility.fasta \
    -input_type fasta \
    -title incompatibility \
    -parse_seqids \
    -hash_index \
    -out incompatibility \
    -max_file_sz 2GB \
    -logfile makeBlastDB.log

```

#### BLAST Software

NCBI (United States National Center for Biotechnology Information) BLAST+ Suite version

2.4.0 (60, 63).

## Step 2. Split Multi-Accession GenBank Files

Input: 1+ GenBank files, each with 1+ records. Each record is itself a GenBank file for a single Accession. Thus, the multi-accession GenBank files are simply concatenations of multiple single-accession GenBank files. Assume that these GenBank files are in a directory called `original_gb`.

Output: One GenBank file for each accession. If the same accession exists in more than one multi-accession file, assume they are the same and overwrite it. Assume that the output GenBank files will be in a directory called `plasmid_gb`.

Code:

### Bash Command

```
cd plasmid_gb
while read ifn
do
    awk -f splitMultiGB.awk "${ifn}"
done <<(ls -1 original_gb/*.gb)
```

### AWK Script (splitMultiGB.awk)

```
#!/bin/awk -f
BEGIN {
    FS="[ ]+";
    accession="";
    ofn="";
}
{
    if ($0 == "/" || $0 == "")
    {
        accession = "";
        ofn = "";
    }
    else if ($1 == "LOCUS")
    {
        accession = $2;
        ofn = accession ".gb";
        print $0 > ofn;
    }
}
```

```

    }
    else
    {
        print $0 >> ofn;
    }
}
END {
    print "done splitting " FILENAME " by accession";
}

```

### Step 3. Extract ORIGIN Sequence from GB to Fasta

Input: One GenBank file with a single accession in it. Assume it is in the directory

`plasmid_gb` and it is named after the pattern `${ACCESSION}.gb`.

Output: One Fasta file with the sequence from the ORIGIN section of the GenBank file. The

Fasta file has sequences that are each on only one line. It will be in the directory

`plasmid_fasta`.

Code:

#### Bash Command

```

while read ifn
do
    ACCESSION=`basename "${ifn}" ".gb"`

    awk -f extractOriginSeqFromGBtoFasta.awk \
        "plasmid_gb/${ACCESSION}.gb" \
        > "plasmid_fasta/${ACCESSION}.fasta"

done <<(ls -1 plasmid_gb/*.gb)

```

#### AWK Script (extractOriginSeqFromGBtoFasta.awk)

```

#!/bin/awk -f

BEGIN {
    FS = "[ ]+";
    origin_found = 0; # false
}

{

```

```

if (origin_found)
{
    sub(/ *[0-9]+ /, "", $0);
    gsub(/ +/, "", $0);
    printf toupper($0);
}
else if ($1 == "ORIGIN")
{
    origin_found = 1; # true

    print ">" gsub(/^(.+)\.gb$/, "\\1", "-1", gsub(/^.*/, "", "-1", FILENAME));
}
}

END {
    printf "\n";
    print "done extracting ORIGIN seq from " FILENAME " to fasta" >
"/dev/stderr";
}

```

#### Step 4. Extract Group Lists

Input: One GenBank file with a multiple accessions in it. Assume it is in the directory

`original_gb` and it is named after the pattern `${GROUP}.gb`.

Output: Multiple text files, each with the extension ".list". Each file is a line separated list of accession numbers that make up the group. The files will be in a directory called `groups` with the name `${GROUP}.list`.

Code:

#### Bash Command

```

while read ifn
do
    awk -f extractGroupLists.awk \
        "${ifn}"
done <<(ls -1 original_gb/*.gb)

```

#### AWK Script (extractGroupLists.awk)

```

#!/bin/awk -f

BEGIN {

```



```

FS="[ ]+";
accession="";
ofn="";
}

{
  if (NR == 1)
  {
    ofn = gensub(/^(.+)\.gb$/, "\\1", "-1", gensub(/^.*\//, "", "-1", FILENAME)) ".list";
  }

  if ($1 == "LOCUS")
  {
    accession = $2;
    print accession >> ofn;
  }
}

END {
  print "done extracting accessions from " FILENAME;
}

```

## Step 5. Blast Incompatibility Groups

Input: Fasta files. Each contains the sequence from a single accession. Assume they are in the directory `plasmid_fasta` and they are named after the pattern `${ACCESSION}.fasta`.

Input: The incompatibility groups BLAST database created in step #1. It is named `incompatibility`.

Output: One tab-separated value file for each input file. Each file is a modified version of the BLAST output format 6. The format is specified as seen using the `-outfmt` option with `blastn`. The columns are as follows: `qseqid`, `sseqid`, `pident`, `length`, `evaluate`, `qframe`, `qlen`, `qstart`, `qend`, `sframe`, `slen`, `sstart`, `send`, `qseq`, and `sseq`. The files will be in a directory called `blast_results` and named after the pattern `${ACCESSION}_fmt6c.tsv`. Note that a match was not included in the output if the percent identity was  $<80\%$ .

Code:

## Bash Command

```
THREADS=8

while read ifn
do
    ACCESSION=`basename "${ifn}" ".fasta"`

    blastn \
        -query "${ifn}" \
        -strand both \
        -task blastn \
        -db incompatibility \
        -out blast_results/${ACCESSION}_fmt6c.tsv \
        -outfmt "6 qseqid sseqid pident length evalue qframe
qlen qstart qend sframe slen sstart send qseq sseq" \
        -num_threads ${THREADS} \
        -perc_identity 80
done <<(ls -1 plasmid_fasta/*.fasta)
```

## BLAST Software

NCBI (United States National Center for Biotechnology Information) BLAST+ Suite version 2.4.0 (60, 63).

### Step 6. Subset BLAST Results by Coverage Cutoff of 60%

Input: Tab-separated value files. Each contains the results from blasting the sequence of a single accession against the incompatibility groups BLAST database. Assume they are in the directory `blast_results` and they are named after the pattern `${ACCESSION}_fmt6c.tsv`.

Output: One tab-separated value file for each input file. Each file is a copy of its respective input file except some results may be omitted if the coverage was less than 60%. The files will be in a directory called `blast_results` and named after the pattern `${ACCESSION}_fmt6c_cov60.tsv`. Note that a new column was inserted as column number 14 (1-based indexing). The columns will now be as follows: qseqid, sseqid, pident, length, evalue, qframe, qlen, qstart, qend, sframe, slen, sstart, send, scov, qseq, and sseq.

Code:

### Bash Command

```
while read ifn
do
    ACCESSION=`basename "${ifn}" "_fmt6c.tsv"`

    awk -f subCovCutoff60.awk \
        "${ifn}" \
        > "blast_results/${ACCESSION}_fmt6c_cov60.tsv"
done <<(ls -1 blast_results/*_fmt6c.tsv)
```

### AWK Script (subCovCutoff60.awk)

```
#!/bin/awk -f

BEGIN {
    FS="\t";
    OFS="\t";
    ORS="\n";
    count=0;
}

{
    # 4 = length, 11 = slen, scov = length / slen
    scov = $4 / $11;
    if (scov >= 0.6)
    {
        count += 1

        # keep 1-13, add new column, keep 14-15 (will become 15-16)
        for (i = 1; i <= 13; i++)
        {
            printf "%s", $i OFS;
        }

        printf "%f", scov OFS;

        for (i = 14; i <= NF; i++)
        {
            printf "%s", $i (i == NF ? ORS : OFS);
        }
    }
}

END {
    print FILENAME ": " count > "/dev/stderr";
}
```

### Step 7. Add Incompatibility Group as Column to BLAST Results

Input: Tab-separated value files. Each contains the results from blasting the sequence of a

single accession against the incompatibility groups BLAST database. It has an added column with the subject coverage and has only records with coverage >60%. Assume they are in the directory `blast_results` and they are named after the pattern

```
${ACCESSION}_fmt6c_cov60.tsv.
```

Output: One tab-separated value file for each input file. Each file is a copy of its respective input file except that an additional column is added. This column has the family or root of the incompatibility group from column #2 (sseqid). The files will be in a directory called `blast_results` and named after the pattern `${ACCESSION}_fmt6c_cov60_fam.tsv`. Note that a new column was inserted as column number 3 (1-based indexing). The columns will now be as follows: qseqid, sseqid, fam, pident, length, evalue, qframe, qlen, qstart, qend, sframe, slen, sstart, send, scov, qseq, and sseq.

Code:

#### Bash Command

```
while read ifn
do
    ACCESSION=`basename "${ifn}" "_fmt6c_cov60.tsv"`

    awk -f addFamCol.awk \
        "${ifn}" \
        > "blast_results/${ACCESSION}_fmt6c_cov60_fam.tsv"
done <<(ls -1 blast_results/*_fmt6c_cov60.tsv)
```

#### AWK Script (addFamCol.awk)

```
#!/bin/awk -f

BEGIN {
    FS="\t";
    OFS="\t";
    ORS="\n";
}

{
    # 2 = subject_id, keep 1-2, add new column, keep 3-16 (will become 4-
```

```

17)
  for (i = 1; i <= 2; i++)
  {
      printf "%s", $i OFS;
  }

  printf "%s", gensub(/^[^(_)+].*$/, "\\1", "-1", $2) OFS;

  for (i = 3; i <= NF; i++)
  {
      printf "%s", $i (i == NF ? ORS : OFS);
  }
}

```

## Step 8. Filter Best Matches in BLAST Results

Input: Tab-separated value files. Each contains the results from blasting the sequence of a single accession against the incompatibility groups BLAST database. It has two added columns with the subject coverage (and has only records with coverage >60%) and family.

Assume they are in the directory `blast_results` and are named after the pattern

```
${ACCESSION}_fmt6c_cov60_fam.tsv.
```

Output: One tab-separated value file for each input file. Each file is a copy of its respective input file except that some results are omitted. The “best” results are retained. “Best” is defined as the result(s) with the highest percent identity and those that have percent identities within only 1 percent of the highest one. The files will be in a directory called

```
blast_results and named after the pattern ${ACCESSION}_fmt6c_cov60_fam_best.tsv.
```

As in the input file, the columns will be as follows: `qseqid`, `sseqid`, `fam`, `pident`, `length`, `evalue`, `qframe`, `qlen`, `qstart`, `qend`, `sframe`, `slen`, `sstart`, `send`, `scov`, `qseq`, and `sseq`.

Code:

### Bash Command

```

while read ifn
do

```

```

ACCESSION=`basename "${ifn}" "_fmt6c_cov60_fam.tsv"`

python3 filterBestResults.py \
    "${ifn}" \
    > "blast_results/${ACCESSON}_fmt6c_cov60_fam_best.tsv"

done <<(ls -1 blast_results/*_fmt6c_cov60_fam.tsv)

```

## Python Version

Python 3.6.4 (<https://www.python.org>).

## Python Script (filterBestResults.py)

```

def handleArgs():
    if len(sys.argv) != 3:
        sys.stderr.write("\n\tERROR: You must provide 2
arguments\n\t\t1- input blast results cov60 fam\n\t\t2- output blast
results file\n\n")
        sys.exit(1)

    input_br = sys.argv[1]
    output_br = sys.argv[2]

    return input_br, output_br

# ==== #
# MAIN #
# ==== #

if __name__ == "__main__":

    import sys

    # handle args
    ibrfn, obrfn= handleArgs()

    # set some handy vars
    records = [] # each line
    per_ids = [] # percent identities (the 4th column)

    with open(ibrfn, 'r') as ifd:
        for line in ifd:
            records.append(line)
            per_ids.append(float(line.rstrip('\n').split('\t')[3]))

    # figure out which ones to keep
    keep = []

    max_per_id = max(per_ids) if len(records) > 0 else 0.0

    for i,per_id in enumerate(per_ids):
        if abs(max_per_id - per_id) <= 1.0:
            keep.append(i)

```

```

# write output
with open (obrfn, 'w') as ofd:
    for i in keep:
        ofd.write(records[i])

# exit
sys.exit(0)

```

## Step 9. Extract Incompatibility Families

Input: Tab-separated value files. Each contains the results from blasting the sequence of a single accession against the incompatibility groups BLAST database. It has two added columns with the subject coverage (and has only records with coverage >60%) and family. Only the “best” results remain. Assume they are in the directory `blast_results` and are named after the pattern `${ACCESSION}_fmt6c_cov60_fam_best.tsv`.

Output: One file for each input file. Each file is a line-delimited list of incompatibility group roots/families. The files will be in a directory called `blast_results` and named after the pattern `${ACCESSION}_families.list`.

Code:

### Bash Command

```

while read ifn
do
    ACCESSION=`basename "${ifn}"`
    "_fmt6c_cov60_fam_best.tsv" `

    cut -f 3 "${ifn}" \
        | sort \
        | uniq \
        > blast_results/"${ACCESSION}_families.list"
done <<(ls -1 blast_results/*_fmt6c_cov60_fam_best.tsv)

```

## Step 10. Extract Plasmid Search Regions

Input: This Python program requires 3 inputs. 1- The accession number of the plasmid it will

extract the search regions from. 2- The directory where the output will be placed. 3- The directory where the GenBank file is located for that plasmid. We assume the GenBank file is named after the pattern `${ACCESSION}.gb`.

Output: One text file containing the lines from input GenBank file that will be searched using the key terms. We assume the output file will be named after the following pattern:

`${ACCESSION}_searchRegions.txt`. For convenience, it will also generate a copy of the input GenBank file with shell color codes, marking the CDS regions in blue, the portions of the CDS regions that will be included in green, and the portion of the CDS regions that will not be searched in red. This file will have the same name as the `.txt` file, but will have the extension `.gb` instead of `.txt`. Note that intended search space is to consider each CDS region as a separate entity. However, only the following subsections of each CDS region are to be considered: `\function`, `\gene`, `\note`, and `\product`.

Code:

Bash Command

```
while read ifn
do
    ACCESSION=`basename "${ifn}" ".gb"`

    python3 extractPlasmidSearchRegions.py \
        "${ACCESSION}" \
        plasmid_searchRegions \
        plasmid_gb
done <<(ls -1 plasmid_gb/*.gb)
```

Python Version

Python 3.6.4 (<https://www.python.org>).

*Python Script (extractPlasmidSearchRegions.py)*



```

# ===== #
# FUNCTIONS #
# ===== #

def handleArgs():
    import sys

    if len(sys.argv) != 4:
        sys.stderr.write("\n\tERROR: You must provide 3
arguments\n\t\tt1- plasmid accession\n\t\tt2- output search regions
dir\n\t\tt3- input gb dir\n\n")
        sys.exit(1)

    plasmid_accession = sys.argv[1]
    output_search_regions_dir = sys.argv[2].rstrip('/')
    input_gb_dir = sys.argv[3].rstrip('/')

    return plasmid_accession, output_search_regions_dir, input_gb_dir

def parseGbFile(input_gb_fn, output_search_regions_fn, output_gb_fn):

    with open (output_search_regions_fn, 'w') as osrd:
        with open(output_gb_fn, 'w') as ogbd:
            red = "\033[0;31m"
            green = "\033[0;32m"
            blue = "\033[0;34m"
            no_color = "\033[0m"

            with open(input_gb_fn, 'r') as ifd:
                section_names = ( "assembly_gap", "CDS",
"gene", "misc_difference", "misc_feature", "misc_recomb",
"mobile_element", "ncRNA", "operon", "oriT", "primer_bind",
"protein_bind", "regulatory", "repeat_region", "rep_origin",
"sig_peptide", "source", "tRNA" )
                subsection_names_of_interest = ( "function",
"gene", "note", "product" )

                # skip from LOCUS to FEATURES
                line = ifd.readline() # grab the first line
("LOCUS")
                while line.rstrip('\n').lstrip(' ').split('
')[0] != "FEATURES":
                    ogbd.write(line)
                    line = ifd.readline()

                # write then skip past FEATURES
                ogbd.write(line)
                line = ifd.readline()

                # skip any lines necessary until CDS or ORIGIN
is found
                tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]

                while tag_word != "ORIGIN" and tag_word !=
"CDS":

```

```

ogbd.write(line)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]

# First time: found ORIGIN or CDS. If ORIGIN,
we're done. If CDS, read through each CDS region, until ORIGIN.
# thereafter: found ORIGIN or CDS or other
section name. If ORIGIN, we're done. If CDS, read through each CDS
region, until ORIGIN. If section name, skip till ORIGIN or next CDS.
while tag_word != "ORIGIN":

# first time: this loop will be
skipped. Thereafter, if a section name (other than CDS), skip to next
CDS or ORIGIN.
while tag_word != "ORIGIN" and tag_word
!= "CDS":
ogbd.write(line)
line = ifd.readline()
tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]

if tag_word == "CDS":
# write the CDS line
osrd.write(line)
ogbd.write(blue + line +
no_color)
else: # if tag_word == "ORIGIN":
break

# skip past the CDS line (guaranteed to
now have a CDS line)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]

# read through important data and stop
at end of CDS (marked by next CDS or ORIGIN or other section name)
# first time: guaranteed inside a CDS
region. Note that a CDS line is NEVER *immediately* followed by another
section name line (at least in our data).
# thereafter: It could be anything
between the CDS and ORIGIN.

while tag_word != "ORIGIN" and tag_word
not in section_names:
if line.rstrip('\n').lstrip('
')[0] == '/': # it is a CDS subsection headerline
subsection_name =
line.strip().split('=')[0].lstrip('/').lower()
subsection =
'='.join(line.strip().split('=')[1:])
if subsection_name in
subsection_names_of_interest: # the subsection is one we care to look
in
osrd.write(line)
ogbd.write(green

```

```

+ line + no_color)

                                                                    if subsection[0]
== '' and subsection[-1] != '': # the subsection spans multiple lines
                                                                    line =
ifd.readline()                                                                    tag_word
= line.rstrip('\n').lstrip(' ').split(' ')[0]
                                                                    while
line.rstrip('\n')[-1] != '': # keep searching to find the end of the
subsection of interest
    osrd.write(line)
    ogbd.write(green + line + no_color)
    line = ifd.readline()
    tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
    osrd.write(line)
    ogbd.write(green + line + no_color)

                                                                    line =
ifd.readline()                                                                    tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
else: # the subsection
is not one we care to look in
                                                                    #if
len(subsection) < 1:
                                                                    #
                                                                    #
                                                                    #
                                                                    #
                                                                    # simple version
that works, but doesn't write it all in red
                                                                    #line =
    #ogbd.write(line)
                                                                    #tag_word =
ifd.readline()
                                                                    # unnecessary
line.rstrip('\n').lstrip(' ').split(' ')[0]
                                                                    ogbd.write(red +
version that actually makes it write it all in red
                                                                    if
line + no_color)
                                                                    if
len(subsection) and subsection[0] == '' and subsection[-1] != '': #
the subsection spans multiple lines

```

```

                                                                    line =
ifd.readline()                                                                    tag_word
= line.rstrip('\n').lstrip(' ').split(' ')[0]
                                                                    while
line.rstrip('\n')[-1] != '"': # keep searching to find the end of the
subsection of interest
    ogbd.write(red + line + no_color)
    line = ifd.readline()
    tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
    ogbd.write(red + line + no_color)
                                                                    line =
ifd.readline()                                                                    tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
                                                                    else: # it is not a CDS
subsection headerline
                                                                    ogbd.write(line)
                                                                    line = ifd.readline()
                                                                    tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
                                                                    # NOTE: the remainder of the file contains the
sequence data
                                                                    ogbd.write(line) # write the ORIGIN
                                                                    ogbd.write(ifd.read()) # write the rest of the
file (i.e., the sequence data)
# ==== #
# MAIN #
# ==== #
if __name__ == "__main__":
    import sys
    # handle args
    plasmid_accession, output_search_regions_dir, input_gb_dir =
handleArgs()
    # set some helpful vars
    osrn = output_search_regions_dir + '/' + plasmid_accession +
"_searchRegions.txt"
    ogbn = output_search_regions_dir + '/' + plasmid_accession +
"_searchRegions.gb"
    igbn = input_gb_dir + '/' + plasmid_accession + ".gb"
    # get CDS info (Antimicrobial Resistance CDS (%) ... Total CDS)
    parseGbFile(igbn, osrn, ogbn)
    # exit
    sys.exit(0)

```

## Step 11. Identify Plasmid Matches

Input: This Python program requires 3 inputs. 1- The accession number of the plasmid in which it will identify matches. 2- The directory where the input search regions file is located. 3- The directory where the output matches will be placed. We assume the input search regions file is named after the pattern `${ACCESSION}_searchRegions.txt`.

Output: One tab-separated value file containing matches. We assume the output file will be named after the following pattern: `${ACCESSION}_matches.tsv`. The columns of the file are as follows:

1. Ignored (True/False)
2. Categories (c1[,c2,...,cN])
3. Search Term
4. CDS Region

Column 1 is a simple flag denoting if the term was to be ignored. This could also be determined based on the second column, but it was convenient to have a simple flag as its own column. Column 2 contains the category (categories) that the search term belonged to. Column 3 contains the regular expression used. Column 4 contains the CDS region that was searched (all tabs and newlines were converted to `\t` (backslash and a t, not a tab) and `\n` (backslash and an n, not a newline) to not interfere with the tab-separated value file format and keep each record on a single line).

Search Strategy: The search terms are each part of one or more categories. It can belong to multiple categories only if the categories are subsets of each other. Five principal categories

exist, two of which have subcategories. The category structure is as follows:

- Antimicrobial Resistance
  - Beta-lactamase
    - Beta-lactamase Special
- Toxin/Antitoxin System
- DNA Maintenance/Modification
  - DNA Maintenance/Modification Special
- Mobile Genetic Elements
- Hypothetical Genes

The strategy could be described as top-to-bottom, in-to-out; i.e., Antimicrobial Resistance is more important than Toxin/Antitoxin System and Beta-lactamase Special is more important than Beta-lactamase and Antimicrobial Resistance. The reason these are shown nested instead of simply above their parents is because a match for a Beta-lactamase Special search term will increment the count for not only itself, but also its parents. If no matches are found, the CDS region being searched is classified as "Other". Some CDS regions will never be searched for these terms if they first match a term in a special "Ignored" category. Provided a CDS region is not to be ignored, it will be searched with Beta-lactamase Special terms, then Beta-lactamase terms, then Antimicrobial Resistance Terms, then Toxin/Antitoxin System terms, and so-forth, until a match is found (thus halting the search on this CDS region) or no more search terms remain (it is assigned to the "Other" category). All CDS regions are converted to lowercase before being searched as described. See Supplementary Table 1 for a table of search terms.

Code:

## Bash Command

```
while read ifn
do
    ACCESSION=`basename "${ifn}" "_searchRegions.txt"`

    python3 identifyPlasmidMatches.py \
        "${ACCESSION}" \
        plasmid_searchRegions \
        plasmid_matches

done <<(ls -1 plasmid_searchRegions/*_searchRegions.txt)
```

## Python Version

Python 3.6.4 (<https://www.python.org>).

## Python Script (identifyPlasmidMatches.py)

```
# ===== #
# FUNCTIONS #
# ===== #

def handleArgs():
    import sys

    if len(sys.argv) != 4:
        sys.stderr.write("\n\tERROR: You must provide 3
arguments\n\t\tt1- plasmid accession\n\t\tt2- input search regions
dir\n\t\tt3- output matches dir\n\n")
        sys.exit(1)

    plasmid_accession = sys.argv[1]
    input_search_regions_dir = sys.argv[2].rstrip('/')
    output_matches_dir = sys.argv[3].rstrip('/')

    return plasmid_accession, input_search_regions_dir, output_matches_dir

def writeLineToMatchesFile(matches_fd, ignored, categories,
search_term, cds_search_region):
    matches_fd.write(str(ignored) + '\t' + ','.join(categories) + '\t' +
search_term + '\t' +
convertCDSsearchRegionToOneLineStr(cds_search_region) + '\n')

def ignoreCDS(cds_search_region, matches_fd):
    key_terms = [ r"truncated", r"interrupted", r"partial", r"disrupted",
r"intron", r"kl\.pn\.i3", r"se\.ma\.[s]", r"morpho",
r"repeat region", r"patho", r"ncrna", r"imperfect",
r"non[ -]?functional", r"is(?:[a-z]{2}|)[0-9]{2,4}" ]
```

```

    return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, True, ["Ignored"])

def betaLactSpecialCopyNum(cds_search_region, matches_fd):
    key_terms = [ r"(?:^[^b-z])ndm", r"(?:^[^b-z])imp(?:$|^[^abc])",
r"(?:^[^b-z])vim", r"(?:^[^b-z])kpc", r"carbapenem[^\s]" ]

    return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Antimicrobial Resistance", "Beta-lactamase",
"Beta-lactamase Special"])

def betaLactSearch(cds_search_region, matches_fd):
    if not betaLactSpecialCopyNum(cds_search_region, matches_fd):

        key_terms = [ r"(?:^[^p])bla", r"beta[ -]lactam[^\s]",
r"(?:^[^p])oxa-",
                    r"(?:^[^p])dha-", r"(?:^[^p])sfo-", r"(?:^[^p])shv-",
r"(?:^[^p])tem-",
                    r"(?:^[^p])ctx-", r"(?:^[^p])ampr", r"(?:^[^p])cmy-",
r"oxacillin[^\s]",
                    r"penicillin[^\s]", r"cephalosporin[^\s]" ]

        return searchCdsRegionForKeyTerms(cds_search_region,
key_terms, matches_fd, False, ["Antimicrobial Resistance", "Beta-
lactamase"])
    else:
        return True

def antimicrobResistSearch(cds_search_region, matches_fd):
    if not betaLactSearch(cds_search_region, matches_fd):

        key_terms = [ r"aac", r"aad", r"aph", r"arr-",
r"resistance", r"aminoglyco[^\s]", r"streptomycin",
r"chloramphenicol",
                    r"cme[abc]", r"catr", r"multidrug", r"efflux pump",
r"mercur[^\s]", r"teller[^\s]", r"arsen[^\s]", r"qace",
r"macrolide", r"mph", r"silver", r"copper",
r"flor", r"ter[abcfw-z](?:$|^[^a-z])",
r"fluoroquino[^\s]", r"bleomycin",
                    r"tetr(?:$|^[^a]|acycline)", r"pco[a-ers]", r"ars[a-
dhr]", r"sil[abcefprs]",
                    r"(?:sulfonamide|trimethoprim|nickel)[ -]resistant",
r"(?:^[^a-z]|^)\folp(?:$|^[^a-z])",
                    r"(?:^[^a-z]|^)\sul[12](?:$|^[^a-z])", r"(?:^[^a-
z]|^)\dfra(?:$|^[^a-z])",
                    r"(?:^[^a-z]|^)\ncr[a-c,y](?:$|^[^a-z])", r"(?:^[^a-
z]|^)\nirb(?:$|^[^a-z])", r"rifamp(?:in|icin)" ]

        return searchCdsRegionForKeyTerms(cds_search_region,
key_terms, matches_fd, False, ["Antimicrobial Resistance"])
    else:
        return True

def plasmidTransferSearch(cds_search_region, matches_fd):
    key_terms = [ r"conjugata[^\s]", r"pili[^\s]", r"pilus", r"type[ -]iv",
r"secretion system", r"fertility inhibition", r"tivb[^\s]",
r"icm[^\s]",

```



```

        r"tra[a-rtuwxy](?:$|^[^a-z])", r"trb[a-gilm]", r"mob[a-e]",
r"fino",
        r"vir[^ugo\s]", r"pilx" ]

    return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Plasmid Transfer"])

def toxinSearch(cds_search_region, matches_fd):
    key_terms = [ r"(?:^[^a-z]|anti)toxi[^\s]", r"stb[de]", r"hig[ab]",
r"cbta",
        r"rel[be]", r"hica", r"yafo", r"ccd[ab]",
        r"abrb", r"par[de]", r"pem[ik]", r"hokg" ]

    return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Toxin System"])

def dnaMaintSpecialCopyNum(cds_search_region, matches_fd):
    key_terms = [ r"muc[ab]", "umu[cd]", "polymerase" ]

    return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["DNA Maintenance", "DNA Maintenance Special"])

def dnaMaintSearch(cds_search_region, matches_fd):
    if not dnaMaintSpecialCopyNum(cds_search_region, matches_fd):

        key_terms = [ r"methylase", r"single-strand binding protein",
r"ssb", r"topb",
            r"replication protein", r"kfra", r"kor[ab]", r"trfa",
            r"helicase", r"dna", r"chromosome", r"entry exclusion",
            r"eex", r"exca", r"nucleoti[^\s]", r"topoisomerase",
            r"integrase", r"(?!ser_line )recombinase",
r"replication", r"nuclease",
            r"relaxase", r"plasmid", r"ruma", r"repa",
            r"uvr[^\s]", r"par[ab]", r"vag[cd]" ]

        return searchCdsRegionForKeyTerms(cds_search_region,
key_terms, matches_fd, False, ["DNA Maintenance"])
    else:
        return True

def mobileGeneticElementsSearch(cds_search_region, matches_fd):
    key_terms = [ r"transpos[^\s]", r"reverse transcriptase", r"tnp",
        r"ist[ab](?:$|^[^a-z0-9])", r"resolvase", "urf2" ]

    return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Mobile Genetic Elements"])

def hypotheticalGenesSearch(cds_search_region, matches_fd):
    key_terms = [ r"hypothetical", r"domain[ -]containing",
r"uncharacterized protein", r"unknown function" ]

    return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Hypothetical Genes"])

def convertCDSsearchRegionToOneLineStr(cds_search_region):
    return "\\n".join(list(map(lambda x: x.replace('\t',
"\t").replace('\n', ""), cds_search_region)))

```

```

def searchCDSRegion(cds_search_region, matches_fd):
# make cds_search_region all lowercase
    cds_search_region = list(map(lambda x: x.lower(), cds_search_region))
# make all the search regions lowercase

    if not ignoreCDS(cds_search_region, matches_fd):
        if not antimicrobResistSearch(cds_search_region, matches_fd):
            if not plasmidTransferSearch(cds_search_region,
matches_fd):
                if not toxinSearch(cds_search_region,
matches_fd):
                    if not
dnaMaintSearch(cds_search_region, matches_fd):
                        if not
mobileGeneticElementsSearch(cds_search_region, matches_fd):
                            if not
hypotheticalGenesSearch(cds_search_region, matches_fd):

                writeLineToMatchesFile(matches_fd, False, ["Other"], "NA",
cds_search_region)

def searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, ignored, categories):
    import re

    for search_sub_region in cds_search_region:
        for key_term in key_terms:
            if re.search(key_term, search_sub_region) is not None:
                writeLineToMatchesFile(matches_fd, ignored,
categories, key_term, cds_search_region)
                return True

    return False

def parseSearchRegionFile(input_sr_fn, matches_fn):
    import re

    with open(input_sr_fn, 'r') as ifd:
        with open(matches_fn, 'w') as mfd:
            mfd.write("Ignored (True/False)\tCategories
(c1[,c2,...,cN])\tSearch Term\tCDS Region\n")

            cds_search_region = []

            # All data is important. Read through all CDS regions
separately and search through them.
            # Each CDS region begins with CDS and ends with another
CDS record or the end of file

            # grab first line (always a CDS line)
            line = ifd.readline()
            tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
            cds_search_region.append(line)

            # grab the next line

```

```

line = ifd.readline()
tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
while line != "":
    while line != "" and tag_word != "CDS":
        cds_search_region.append(line)
        line = ifd.readline()
        tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]

    # search the region
    searchCDSRegion(cds_search_region, mfd)
    cds_search_region = []

    # grab the next line
    cds_search_region.append(line)
    line = ifd.readline()
    tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]

# ==== #
# MAIN #
# ==== #

if __name__ == "__main__":

    import sys

    # handle args
    plasmid_accession, input_search_regions_dir, output_matches_dir =
handleArgs()

    # set some helpful vars
    isrn = input_search_regions_dir + '/' + plasmid_accession +
"_searchRegions.txt"
    mfn = output_matches_dir + '/' + plasmid_accession + "_matches.tsv"

    # search the search regions file for matches
    parseSearchRegionFile(isrn, mfn)

    # exit
    sys.exit(0)

```

## Step 12. Generate Plasmid CSVs

Input: This Python program requires 5 inputs. 1- The accession number of the plasmid it will generate a CSV file for. 2- The directory where the output CSV file is to be placed. 3- The directory where the plasmid fasta file is located. We assume it is named after the pattern `${ACCESSION}.fasta`. 4- The directory where the input plasmid matches file is located. We assume it is named after the pattern `${ACCESSION}_matches.tsv`. 5- The directory where

the input incompatibility groups (derived from the BLAST results) are located. We assume it is named after the pattern `${ACCESSION}_families.list`.

Output: One comma-separated value file. It will be placed in the directory specified in the input position 2. We assume the output file will be named after the following pattern:

`${ACCESSION}.csv`. The columns of the file are as follows:

"Accession #", "Plasmid Length", "Antimicrobial Resistance CDS", "Antimicrobial Resistance CDS %", "Beta-lactamase CDS", "Beta-lactamase CDS %", "Beta-lactamase Special (Carbapenem\*,IMP,KPC,NDM,VIM) Copy #", "Beta-lactamase Special (Carbapenem\*,IMP,KPC,NDM,VIM) Copy # % of Beta-lactamase", "Beta-lactamase Special (Carbapenem\*,IMP,KPC,NDM,VIM) Absent (Yes/No)", "Plasmid Transfer CDS", "Plasmid Transfer CDS %", "Toxin/Antitoxin System CDS", "Toxin/Antitoxin System CDS %", "Toxin/Antitoxin System Present (Yes/No)", "DNA Maintenance/Modification CDS", "DNA Maintenance/Modification CDS %", "DNA Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD) Copy #", "DNA Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD) Copy # % of DNA Maintenance/Modification", "DNA Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD) Copy # % of Total", "DNA Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD) Present (Yes/No)", "Mobile Genetic Elements CDS", "Mobile Genetic Elements CDS %", "Hypothetical Genes CDS", "Hypothetical Genes CDS %", "Other CDS", "Other CDS %", "Total CDS", "Incompatibility Groups"

Code:

## Bash Command

```
while read ifn
do
    ACCESSION=`basename "${ifn}" ".fasta"`

    python3 generatePlasmidCSV.py \
        "${ACCESSION}" \
        plasmid_csv \
        plasmid_fasta \
        plasmid_matches \
        blast_results

done <<(ls -1 plasmid_fasta/*.fasta)
```

## Python Version

Python 3.6.4 (<https://www.python.org>).

## Python Script (generatePlasmidCSV.py)

```
# ===== #
# FUNCTIONS #
# ===== #

def handleArgs():
    import sys

    if len(sys.argv) != 6:
        sys.stderr.write("\n\tERROR: You must provide 5
arguments\n\t\t1- plasmid accession\n\t\t2- output csv dir\n\t\t3-
input fasta dir\n\t\t4- input matches dir\n\t\t5- input incompatibility
groups blast output dir\n\n")
        sys.exit(1)

    plasmid_accession = sys.argv[1]
    output_csv_dir = sys.argv[2].rstrip('/')
    input_fasta_and_length_dir = sys.argv[3].rstrip('/')
    input_matches_dir = sys.argv[4].rstrip('/')
    input_incompatibility_groups_blast_output_dir =
sys.argv[5].rstrip('/')

    return plasmid_accession, output_csv_dir, input_fasta_and_length_dir,
input_matches_dir, input_incompatibility_groups_blast_output_dir

def CSVify(some_str):
    return "'" + some_str + "'"

def getPlasmidLength(input_length_fn):
    with open(input_length_fn, 'r') as ifd:
        return int(ifd.readline().rstrip('\n'))

def getRegionCounts(categories):
    cats = [ "Antimicrobial Resistance", "Beta-lactamase", "Beta-lactamase
```

```

Special",
    "Plasmid Transfer", "Toxin System", "DNA Maintenance",
    "DNA Maintenance Special", "Mobile Genetic Elements",
"Hypothetical Genes", "Other" ]

counts = [0] * len(cats)

category_counts = {}

for category in sorted(categories):
    if not category in category_counts:
        category_counts[category] = 0
    category_counts[category] += 1

for i,cat in enumerate(cats):
    counts[i] = category_counts[cat] if cat in category_counts
else 0

return counts

def updateCDScounts(cds_counts, cds_region_counts):
    for i,cds_region_count in enumerate(cds_region_counts):
        cds_counts[i] += cds_region_count

    return cds_counts

def parseMatchesFile(matches_fn):
    import re

    with open(matches_fn, 'r') as ifd:
        cds_counts = [0] * 10 # 10 CDS related columns in output

        # skip past the TSV header line
        ifd.readline()

        # grab first data line
        line = ifd.readline()

        while line != "":
            fields = line.rstrip('\n').split('\t')

            ignore = True if fields[0] == "True" else False
            categories = fields[1].split(',')
            key_term = fields[2]
            cds_search_region = fields[3]

            if not ignore:
                cds_counts = updateCDScounts(cds_counts,
getRegionCounts(categories) )

            # grab the next line
            line = ifd.readline()
            tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]

        return cds_counts

```

```

def getPercentOfTotal(count, total):
    if total:
        return count / total
    else:
        return "NA"

def convertCdsInfoToOutputStr(antimicrob_resist_cds_count,
beta_lact_cds_count, beta_lact_special_copy_num,
plasmid_transfer_cds_count, \
    toxin_cds_count, dna_maint_cds_count,
dna_maint_special_copy_num, mobile_genetic_elements_cds_count, \
    hypothetical_genes_cds_count, other_cds_count):

    # initialize output list (will eventually become a giant string). Each
item will need to be easily converted to a string using str.
    output = []

    # find the total num of cds regions
    total_cds_count = sum((antimicrob_resist_cds_count,
plasmid_transfer_cds_count, toxin_cds_count, \
        dna_maint_cds_count, mobile_genetic_elements_cds_count,
hypothetical_genes_cds_count, other_cds_count))

    # append columns to output

    #     antimicrob resist (w/ beta lact)
    #     antimicrob resist
    output.append(antimicrob_resist_cds_count) # count
    output.append(getPercentOfTotal(antimicrob_resist_cds_count,
total_cds_count)) # percent of total
    #     beta lact
    output.append(beta_lact_cds_count) # count
    output.append(getPercentOfTotal(beta_lact_cds_count, total_cds_count))
# percent of total
    #     special copy num
    output.append(beta_lact_special_copy_num) # count
    output.append(getPercentOfTotal(beta_lact_special_copy_num,
beta_lact_cds_count)) # percent of beta lact
    output.append(getPercentOfTotal(beta_lact_special_copy_num,
total_cds_count)) # percent of total
    output.append("No" if beta_lact_special_copy_num else "Yes") # absent
(Yes/No)

    #     plasmid transfer
    output.append(plasmid_transfer_cds_count) # count
    output.append(getPercentOfTotal(plasmid_transfer_cds_count,
total_cds_count)) # percent of total

    #     toxin system
    output.append(toxin_cds_count) # count
    output.append(getPercentOfTotal(toxin_cds_count, total_cds_count)) #
percent of total
    output.append("Yes" if toxin_cds_count else "No") # present (Yes/No)

    #     dna maint
    output.append(dna_maint_cds_count) # count
    output.append(getPercentOfTotal(dna_maint_cds_count, total_cds_count))

```

```

# percent of total
#         special copy num
output.append(dna_maint_special_copy_num) # count
output.append(getPercentOfTotal(dna_maint_special_copy_num,
dna_maint_cds_count)) # percent of dna maint
output.append(getPercentOfTotal(dna_maint_special_copy_num,
total_cds_count)) # percent of total
output.append("Yes" if dna_maint_special_copy_num else "No") # present
(Yes/No)

#         mobile genetic elements
output.append(mobile_genetic_elements_cds_count) # count
output.append(getPercentOfTotal(mobile_genetic_elements_cds_count,
total_cds_count)) # percent of total

#         hypothetical genes
output.append(hypothetical_genes_cds_count) # count
output.append(getPercentOfTotal(hypothetical_genes_cds_count,
total_cds_count)) # percent of total

#         other (/unknown)
output.append(other_cds_count) # count
output.append(getPercentOfTotal(other_cds_count, total_cds_count)) #
percent of total

#         total
output.append(total_cds_count) # count

# convert all elements to str, join by ",", and add leading and
trailing "
output = CSVify("\",\"").join(list(map(str, output)))

# return
return output

def getIncompatibilityGroups(input_incompatibility_groups_fn):
    with open(input_incompatibility_groups_fn, 'r') as ifd:
        return [line.rstrip('\n') for line in ifd]

# ==== #
# MAIN #
# ==== #

if __name__ == "__main__":

    import sys

    # handle args
    plasmid_accession, output_csv_dir, input_fasta_and_length_dir,
input_matches_dir, input_incompatibility_groups_blast_output_dir =
handleArgs()

    # set some helpful vars
    ocn = output_csv_dir + '/' + plasmid_accession + ".csv"
    ifn = input_fasta_and_length_dir + '/' + plasmid_accession + ".fasta"
    iln = input_fasta_and_length_dir + '/' + plasmid_accession + ".length"
    mfn = input_matches_dir + '/' + plasmid_accession + "_matches.tsv"

```



```

iign = input_incompatibility_groups_blast_output_dir + '/' +
plasmid_accession + "_families.list"

csv_header = [ "Accession #",
               "Plasmid Length",
               "Antimicrobial Resistance CDS", "Antimicrobial Resistance CDS
%",
               "Beta-lactamase CDS", "Beta-lactamase CDS %", "Beta-lactamase
Special (Carbapenem*,IMP,KPC,NDM,VIM) Copy #", "Beta-lactamase Special
(Carbapenem*,IMP,KPC,NDM,VIM) Copy # % of Beta-lactamase", "Beta-
lactamase Special (Carbapenem*,IMP,KPC,NDM,VIM) Copy # % of Total",
"Beta-lactamase Special (Carbapenem*,IMP,KPC,NDM,VIM) Absent (Yes/No)",
               "Plasmid Transfer CDS", "Plasmid Transfer CDS %",
               "Toxin/Antitoxin System CDS", "Toxin/Antitoxin System CDS %",
"Toxin/Antitoxin System Present (Yes/No)",
               "DNA Maintenance/Modification CDS", "DNA
Maintenance/Modification CDS %", "DNA Maintenance/Modification Special
(mucA,mucB,polymerase,umuC,umuD) Copy #", "DNA Maintenance/Modification
Special (mucA,mucB,polymerase,umuC,umuD) Copy # % of DNA
Maintenance/Modification", "DNA Maintenance/Modification Special
(mucA,mucB,polymerase,umuC,umuD) Copy # % of Total", "DNA
Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD)
Present (Yes/No)",
               "Mobile Genetic Elements CDS", "Mobile Genetic Elements CDS
%",
               "Hypothetical Genes CDS", "Hypothetical Genes CDS %",
               "Other CDS", "Other CDS %",
               "Total CDS",
               "Incompatibility Groups" ]

# get necessary information
# get CSV Header
csv_header_output_str = CSVify("\",\"").join(csv_header)

# get plasmid accession #
plasmid_accession_output_str = CSVify(plasmid_accession)

# get plasmid length
plasmid_length = getPlasmidLength(iln)
plasmid_length_output_str = CSVify(str(plasmid_length))

# get CDS info (Antimicrobial Resistance CDS (%) ... Total CDS)
cds_info = parseMatchesFile(mfn)
cds_info_output_str = convertCdsInfoToOutputStr(*cds_info)

# get incompatibility groups
incompatibility_groups = getIncompatibilityGroups(iign)
incompatibility_groups_output_str =
CSVify(',').join(incompatibility_groups) if len(incompatibility_groups)
> 0 else CSVify("NA")

# write output
with open (ocn, 'w') as ocd:
    # csv header line
    ocd.write(csv_header_output_str + '\n') # csv header

    # csv data line

```

```

        ocd.write(plasmid_accession_output_str + ',') # accession #
        ocd.write(plasmid_length_output_str + ',') # plasmid length
        ocd.write(cds_info_output_str + ',') # CDS info (Antimicrobial
Resistance CDS (%) ... Total CDS)
        ocd.write(incompatibility_groups_output_str + '\n') #
incompatibility groups

# exit
sys.exit(0)

```

### Step 13. Create CSVs from Plasmid CSVs

**Input:** The inputs required are the group list files that contain the plasmids in each group (see step #4) and the individual plasmid CSVs (see step #12). The group list files are assumed to be in the directory `groups` and named after the pattern `${GROUP}.list`. The plasmid CSVs are assumed to be in the `plasmid_csv` directory and named after the pattern

```

${ACCESSION}.csv.

```

**Output:** One comma-separated value file containing the same header line as all the plasmid CSVs and a concatenation of the non-header lines from the plasmid CSVs. We assume the output file will be in the directory `group_csv` and will be named after the following pattern:

```

${GROUP}.csv.

```

**Code:**

#### Bash Command

```

while read ifn
do
    GROUP=`basename "${ifn}" ".list"`
    ofn="group_csv/${GROUP}.csv"

    # get and write a header
    hfn=plasmid_csv/`head -q -n 1 "${ifn}"`.csv"
    head -q -n 1 "${hfn}" > "${ofn}"

    # get and write the non-headers lines
    nhfns=`cat "${ifn}" | sed -r 's,^(.+)$,plasmid_csv/\1.csv,' |
tr '\n' ' '`
    tail -q -n +2 ${nhfns} >> "${ofn}"

done <<(ls -l groups/*.list)

```

### *sed Note*

sed must be GNU (<https://www.gnu.org>) sed. `-r` does not enable extended regular expression syntax with BSD (<http://www.bsd.org>) sed.

## Step 14. Create Group Matches from Plasmid Matches

Note that this step is not technically necessary to generate the desired output (the group CSV files (step #13) and the group statistics files (step #15)). This is really for convenience in inspecting results.

Input: The inputs required are the group list files that contain the plasmids in each group (see step #4) and the individual plasmid matches (see step #11). The group list files are assumed to be in the directory `groups` and named after the pattern `${GROUP}.list`. The plasmid matches are assumed to be in the `plasmid_matches` directory and named after the pattern `${ACCESSION}_matches.tsv`.

Output: One text file containing the matches for the group. We assume the output file will be in the directory `group_matches` and will be named after the following pattern:

`${GROUP}_matches.tsv`.

Code:

### *Bash Command*

```
while read ifn
do
    GROUP=`basename "${ifn}" ".list"`
    ofn="group_matches/${GROUP}_matches.tsv"

    fns=`cat "${ifn}" | sed -r
's,^(.+)$,plasmid_matches/\1_matches.tsv,' | tr '\n' ' '`
    head -q -n 1 ${fns} | head -n 1 > "${ofn}"
    tail -q -n +2 ${fns} >> "${ofn}"
done <<(ls -1 groups/*.list)
```

### *sed Note*

sed must be GNU (<https://www.gnu.org>) sed. `-r` does not enable extended regular expression syntax with BSD (<http://www.bsd.org>) sed

### Step 15. Calculate Group Statistics from Group CSV

Input: This Python program requires 2 inputs. 1- The CSV file for a group. Here, we show the CSV files in the directory `group_csv`, named after the pattern `${GROUP}.csv`. 2- The output statistics file for the group. Here, we show the statistics files in the directory `group_stats`, named after the pattern `${GROUP}.stats`.

Output: One text file named as described in position 2 of the input to the Python program.

That file is formatted as follows:

```
GROUP_NAME
====
Total # of Plasmids: ##

Incompatibility Groups Structure:
  Inc.          Plasmid   Size          Size
  Group         Count     Mean          St. Dev.
  IncGrp1       #         #.###        #.###
  IncGrp2       #         #####.###    #####.###
  .
  .
  .
  IncGrpN       #         #####.###    #####.###

Plasmids Summary:
  Min: #####
  Max: #####
  Median: #####
  Mean: #####.###
  St. Dev.: #####.###

Key Words Structure:
  Key          Plasmid   Size          Size
  Word         Count     Mean          St. Dev.
  anti_microb_resist    ##         #####.###    #####.###
  anti_microb_resist_not #         #####.###    #####
  beta_lact        ##         #####.###    #####.###
  beta_lact_not    #         #####.###    #####
  plasmid_transfer  ##         #####.###    #####.###
  plasmid_transfer_not #         #####.###    #####.###
```

```

toxin          ##          #####.###  #####.###
toxin_not     ##          #####.###  #####.###
dna_maint     ##          #####.###  #####.###
dna_maint_not #          #####.###  #####
mob_gen_elem  ##          #####.###  #####.###
mob_gen_elem_not #        #####.###  #####.###
hypo_genes   ##          #####.###  #####.###
hypo_genes_not #        #####.###  #####
other        ##          #####.###  #####.###
other_not    #          #####.###  #####.###

```

Plasmid Structure:

This information is already reported in the CSV file: GROUP\_NAME.csv

Code:

### *Bash Command*

```

while read gfn
do
    GROUP=`basename "${gfn}" ".list"`

    ifn="group_csv/${GROUP}.csv"
    ofn="group_stats/${GROUP}.stats"

    python3 calcGroupCSVstats.py\
        "${ifn}" \
        "${ofn}"
done <<(ls -1 groups/*.list)

```

### Python Version

Python 3.6.4 (<https://www.python.org>).

### Python Script (calcGroupCSVstats.py)

```

#####
# FUNCTIONS #
#####

def handleArgs(args, sefd, sext):
    if len(args) != 3:
        sefd.write("\n\tERROR: Incorrect arguments\n\t\tt1- input group
csv file\n\t\tt2- output text file\n\n")
        sext(1)

    ifn = sys.argv[1]
    ofn = sys.argv[2]

    return ifn, ofn

def writeIncGroupsStructure(ofd, inc_groups):

```

```

output = []
sizes = []

header1 = ("Inc.", "Plasmid", "Size", "Size")
header2 = ("Group", "Count", "Mean", "St. Dev.")

output.append(header1)
sizes.append(tuple(map(len, output[-1])))
output.append(header2)
sizes.append(tuple(map(len, output[-1])))

for inc_group in sorted(inc_groups.keys()):
    if inc_group != "NA":
        lengths = inc_groups[inc_group]
        count = len(lengths)
        mean = count
        st_dev = 0
        if count > 1:
            mean = stats.mean(lengths)
            st_dev = stats.stdev(lengths)
        output.append((inc_group, str(count),
"{0:.3f}".format(mean), "{0:.3f}".format(st_dev)))
        sizes.append(tuple(map(len, output[-1])))

c0 = 0
c1 = 0
c2 = 0
c3 = 0
for size in sizes:
    if size[0] > c0:
        c0 = size[0]
    if size[1] > c1:
        c1 = size[1]
    if size[2] > c2:
        c2 = size[2]
    if size[3] > c3:
        c3 = size[3]

ofd.write("Incompatibility Groups Structure:\n")
for o,s in zip(output,sizes):
    ofd.write('\t')
    ofd.write(o[0] + ' ' * (c0 - s[0] + 3))
    ofd.write(o[1] + ' ' * (c1 - s[1] + 3))
    ofd.write(o[2] + ' ' * (c2 - s[2] + 3))
    ofd.write(o[3] + ' ' * (c3 - s[3] + 3))
    ofd.write('\n')

def getGroupStructureMeanStr(lengths):
    if len(lengths) > 0:
        return "{0:.3f}".format(stats.mean(lengths))
    else:
        return "NA"

def getGroupStructureStDevStr(lengths):
    if len(lengths) > 1:
        return "{0:.3f}".format(stats.stdev(lengths))
    elif len(lengths) < 1: # == 0

```

```

        return "NA"
    else: # == 1
        return str(lengths[0])

def writeGroupStructure(ofd, all_group_structure_fields):

    # set up the group structure arrays (to be populated with plasmid
    lengths)
    anti_microb_resist = []
    anti_microb_resist_not = []
    beta_lact = []
    beta_lact_not = []
    plasmid_transfer = []
    plasmid_transfer_not = []
    toxin = []
    toxin_not = []
    dna_maint = []
    dna_maint_not = []
    mob_gen_elem = []
    mob_gen_elem_not = []
    hypo_genes = []
    hypo_genes_not = []
    other = []
    other_not = []

    # extract the information and load it into the group structure arrays
    for group_structure_fields in all_group_structure_fields:
        # if three is a count, add it. else add it to the not. We're
        adding the length.
        length = group_structure_fields[0]
        anti_microb_resist_count = group_structure_fields[1]
        beta_lact_count = group_structure_fields[2]
        plasmid_transfer_count = group_structure_fields[3]
        toxin_count = group_structure_fields[4]
        dna_maint_count = group_structure_fields[5]
        mob_gen_elem_count = group_structure_fields[6]
        hypo_genes_count = group_structure_fields[7]
        other_count = group_structure_fields[8]

        if anti_microb_resist_count:
            anti_microb_resist.append(length)
        else:
            anti_microb_resist_not.append(length)
        if beta_lact_count:
            beta_lact.append(length)
        else:
            beta_lact_not.append(length)
        if plasmid_transfer_count:
            plasmid_transfer.append(length)
        else:
            plasmid_transfer_not.append(length)
        if toxin_count:
            toxin.append(length)
        else:
            toxin_not.append(length)
        if dna_maint_count:
            dna_maint.append(length)

```

```

else:
    dna_maint_not.append(length)
if mob_gen_elem_count:
    mob_gen_elem.append(length)
else:
    mob_gen_elem_not.append(length)
if hypo_genes_count:
    hypo_genes.append(length)
else:
    hypo_genes_not.append(length)
if other_count:
    other.append(length)
else:
    other_not.append(length)

# for each of the arrays, calc mean & st. dev., write to file

#     calc
anti_microb_resist_mean_str =
getGroupStructureMeanStr(anti_microb_resist)
anti_microb_resist_stdev_str =
getGroupStructureStDevStr(anti_microb_resist)
anti_microb_resist_not_mean_str =
getGroupStructureMeanStr(anti_microb_resist_not)
anti_microb_resist_not_stdev_str =
getGroupStructureStDevStr(anti_microb_resist_not)
beta_lact_mean_str = getGroupStructureMeanStr(beta_lact)
beta_lact_stdev_str = getGroupStructureStDevStr(beta_lact)
beta_lact_not_mean_str = getGroupStructureMeanStr(beta_lact_not)
beta_lact_not_stdev_str = getGroupStructureStDevStr(beta_lact_not)
plasmid_transfer_mean_str = getGroupStructureMeanStr(plasmid_transfer)
plasmid_transfer_stdev_str =
getGroupStructureStDevStr(plasmid_transfer)
plasmid_transfer_not_mean_str =
getGroupStructureMeanStr(plasmid_transfer_not)
plasmid_transfer_not_stdev_str =
getGroupStructureStDevStr(plasmid_transfer_not)
toxin_mean_str = getGroupStructureMeanStr(toxin)
toxin_stdev_str = getGroupStructureStDevStr(toxin)
toxin_not_mean_str = getGroupStructureMeanStr(toxin_not)
toxin_not_stdev_str = getGroupStructureStDevStr(toxin_not)
dna_maint_mean_str = getGroupStructureMeanStr(dna_maint)
dna_maint_stdev_str = getGroupStructureStDevStr(dna_maint)
dna_maint_not_mean_str = getGroupStructureMeanStr(dna_maint_not)
dna_maint_not_stdev_str = getGroupStructureStDevStr(dna_maint_not)
mob_gen_elem_mean_str = getGroupStructureMeanStr(mob_gen_elem)
mob_gen_elem_stdev_str = getGroupStructureStDevStr(mob_gen_elem)
mob_gen_elem_not_mean_str = getGroupStructureMeanStr(mob_gen_elem_not)
mob_gen_elem_not_stdev_str =
getGroupStructureStDevStr(mob_gen_elem_not)
hypo_genes_mean_str = getGroupStructureMeanStr(hypo_genes)
hypo_genes_stdev_str = getGroupStructureStDevStr(hypo_genes)
hypo_genes_not_mean_str = getGroupStructureMeanStr(hypo_genes_not)
hypo_genes_not_stdev_str = getGroupStructureStDevStr(hypo_genes_not)
other_mean_str = getGroupStructureMeanStr(other)
other_stdev_str = getGroupStructureStDevStr(other)
other_not_mean_str = getGroupStructureMeanStr(other_not)

```



```

other_not_stdev_str = getGroupStructureStDevStr(other_not)

#       write to file
ofd.write("Key Words Structure:\n")

#               create columned output
output = []
sizes = []

header1 = ("Key", "Plasmid", "Size", "Size")
header2 = ("Word", "Count", "Mean", "St. Dev.")
output.append(header1)
output.append(header2)

output.append( ( "anti_microb_resist", str(len(anti_microb_resist)),
anti_microb_resist_mean_str, anti_microb_resist_stdev_str ) )
output.append( ( "anti_microb_resist_not",
str(len(anti_microb_resist_not)), anti_microb_resist_not_mean_str,
anti_microb_resist_not_stdev_str ) )
output.append( ( "beta_lact", str(len(beta_lact)), beta_lact_mean_str,
beta_lact_stdev_str ) )
output.append( ( "beta_lact_not", str(len(beta_lact_not)),
beta_lact_not_mean_str, beta_lact_not_stdev_str ) )
output.append( ( "plasmid_transfer", str(len(plasmid_transfer)),
plasmid_transfer_mean_str, plasmid_transfer_stdev_str ) )
output.append( ( "plasmid_transfer_not",
str(len(plasmid_transfer_not)), plasmid_transfer_not_mean_str,
plasmid_transfer_not_stdev_str ) )
output.append( ( "toxin", str(len(toxin)), toxin_mean_str,
toxin_stdev_str ) )
output.append( ( "toxin_not", str(len(toxin_not)), toxin_not_mean_str,
toxin_not_stdev_str ) )
output.append( ( "dna_maint", str(len(dna_maint)), dna_maint_mean_str,
dna_maint_stdev_str ) )
output.append( ( "dna_maint_not", str(len(dna_maint_not)),
dna_maint_not_mean_str, dna_maint_not_stdev_str ) )
output.append( ( "mob_gen_elem", str(len(mob_gen_elem)),
mob_gen_elem_mean_str, mob_gen_elem_stdev_str ) )
output.append( ( "mob_gen_elem_not", str(len(mob_gen_elem_not)),
mob_gen_elem_not_mean_str, mob_gen_elem_not_stdev_str ) )
output.append( ( "hypo_genes", str(len(hypo_genes)),
hypo_genes_mean_str, hypo_genes_stdev_str ) )
output.append( ( "hypo_genes_not", str(len(hypo_genes_not)),
hypo_genes_not_mean_str, hypo_genes_not_stdev_str ) )
output.append( ( "other", str(len(other)), other_mean_str,
other_stdev_str ) )
output.append( ( "other_not", str(len(other_not)), other_not_mean_str,
other_not_stdev_str ) )

for o in output:
    sizes.append( tuple(map(len, o)))

c0 = 0
c1 = 0
c2 = 0
c3 = 0
for size in sizes:

```

```

        if size[0] > c0:
            c0 = size[0]
        if size[1] > c1:
            c1 = size[1]
        if size[2] > c2:
            c2 = size[2]
        if size[3] > c3:
            c3 = size[3]

#           actually write to file
for o,s in zip(output,sizes):
    ofd.write('\t')
    ofd.write(o[0] + ' ' * (c0 - s[0] + 3))
    ofd.write(o[1] + ' ' * (c1 - s[1] + 3))
    ofd.write(o[2] + ' ' * (c2 - s[2] + 3))
    ofd.write(o[3] + ' ' * (c3 - s[3] + 3))
    ofd.write('\n')

#####
# MAIN #
#####
if __name__ == "__main__":

    import sys
    import statistics as stats

    ifn, ofn = handleArgs(sys.argv, sys.stderr, sys.exit)

    group_name = '.'.join(ifn.strip().split('/')[ -1].split('.')[: -1])

    with open(ofn, 'w') as ofd:

        # write the groupname title to the output
        ofd.write(group_name + '\n' + '=' * len(group_name) + '\n')

        # parse the input file and extract necessary information
        with open(ifn, 'r') as ifd:

            # skip past header line
            ifd.readline()

            # set some handy vars
            total_number_of_plasmids = 0
            plasmid_lengths = []
            all_inc_groups = {}
            all_group_structure_fields = []

            # loop through each plasmid_record (line) in the input
            for plasmid_record in ifd:
                # increment the total num of plasmids (one
                # plasmid exists per line)
                total_number_of_plasmids += 1

                # split the record into its 28 separate
                # columns/fields
                fields =

```

```

plasmid_record.rstrip('\n').rstrip('').lstrip('').split("\",\"")

        plasmid_accession = fields[0].strip('')
        plasmid_length = int(fields[1].strip(''))
        inc_groups = fields[28].strip('').split(',')
        group_structure_fields = tuple(map(lambda
field: int(field.strip('')), (fields[1], fields[2], fields[4],
fields[10], fields[12], fields[15], fields[21], fields[23],
fields[25])))

        # capture length information
        plasmid_lengths.append(plasmid_length)

        # capture info about inc groups
        for inc_group in inc_groups:
            if inc_group not in all_inc_groups:
                all_inc_groups[inc_group] = []

all_inc_groups[inc_group].append(plasmid_length)

        # capture info about group structure

all_group_structure_fields.append(group_structure_fields)

        # write stuff to the output file
        # total number of plasmids
        ofd.write("Total # of Plasmids: " +
str(total_number_of_plasmids) + '\n')
        ofd.write('\n') # extra newline

        # inc groups structure
        writeIncGroupsStructure(ofd, all_inc_groups)
        ofd.write('\n') # extra newline

        # group plasmids size
        ofd.write("Plasmids Summary:\n")
        ofd.write("\t    Min: " + str(min(plasmid_lengths)) + '\n')
        ofd.write("\t    Max: " + str(max(plasmid_lengths)) + '\n')
        ofd.write("\t    Median: " + str(stats.median(plasmid_lengths))
+ '\n')
        ofd.write("\t    Mean: " +
"{0:.3f}".format(stats.mean(plasmid_lengths)) + '\n')
        ofd.write("\tSt. Dev.: " +
"{0:.3f}\n".format(stats.stdev(plasmid_lengths)) if
len(plasmid_lengths) > 1 else '0' + '\n')
        ofd.write('\n') # extra newline

        # group structure
        writeGroupStructure(ofd, all_group_structure_fields)
        ofd.write('\n') # extra newline

        # plasmid structure
        ofd.write("Plasmid Structure:\n")
        ofd.write("\tThis information is already reported in the CSV
file: " + ifn.split('/')[ -1] + '\n')
        ofd.write('\n') # extra newline

```

## APPENDIX C

TABLE 4: CR-plasmid accession numbers

								Accession #
CP008933	CP006661	CP018974	CP021534	CP021961	CP024836	CP026577	JX101693	KF732966
KX214669	CP006799	CP018977	CP021536	CP021962	CP024840	CP026584	JX104759	KF874496
KX214670	CP012902	CP018981	CP021546	CP022126	CP025006	CP026589	JX104760	KF874497
KX214671	CP012990	CP018989	CP021548	CP022574	CP025009	CP026590	JX193301	KF874498
KP873171	CP014757	CP018992	CP021682	CP022693	CP025010	EU855787	JX193302	KF874499
CP010881	CP015835	CP018999	CP021687	CP023488	CP025039	EU855788	JX283456	KF914891
CP025626	CP015991	CP019001	CP021692	CP023554	CP025141	FJ628167	JX397875	KF954759
KT362706	CP016035	CP019006	CP021699	CP023871	CP025144	GU585907	JX424614	KF954760
MF353156	CP016402	CP019010	CP021709	CP023895	CP025147	GU595196	JX430448	KF976405
AB616660	CP016403	CP019014	CP021716	CP023910	CP025148	HF955507	JX442975	KF977034
AB759690	CP016921	CP019017	CP021720	CP023914	CP025458	HG969995	JX461340	KF992018
AP012055	CP017937	CP019026	CP021734	CP023923	CP025463	HG969996	JX988621	KF998104
AP012208	CP017981	CP019053	CP021738	CP023926	CP025467	HG969997	KC311431	KJ146687
AP013064	CP018366	CP019073	CP021743	CP023928	CP025468	HG969998	KC405622	KJ146688
AP018137	CP018426	CP019774	CP021750	CP023938	CP025517	HG969999	KC788405	KJ146689
AP018138	CP018432	CP020049	CP021754	CP023942	CP025710	HQ451074	KC845573	KJ187751
AP018139	CP018436	CP020056	CP021756	CP023948	CP025948	HQ589350	KC887916	KJ187752
AP018141	CP018668	CP020059	CP021759	CP023952	CP025952	JF503991	KC887917	KJ413946
AP018142	CP018669	CP020066	CP021778	CP023959	CP025964	JF714412	KC958437	KJ440075
AP018143	CP018675	CP020068	CP021835	CP024039	CP025965	JF785549	KC999035	KJ440076
AP018144	CP018817	CP020075	CP021860	CP024192	CP026175	JN157804	KF017315	KJ577613
AP018146	CP018884	CP020110	CP021861	CP024522	CP026179	JN233705	KF182187	KJ588779
AP018147	CP018887	CP020119	CP021881	CP024529	CP026201	JN420336	KF220657	KJ653815
AP018454	CP018945	CP020848	CP021899	CP024557	CP026204	JN687470	KF220658	KJ721789
AP018455	CP018949	CP020854	CP021900	CP024805	CP026205	JN861072	KF250428	KJ721790
CP003224	CP018956	CP020902	CP021936	CP024818	CP026394	JQ349086	KF295829	KJ802404
CP003997	CP018959	CP021177	CP021941	CP024825	CP026395	JQ364967	KF534788	KJ802405
CP004366	CP018963	CP021206	CP021947	CP024828	CP026401	JQ824049	KF623109	KJ812998
CP004367	CP018968	CP021210	CP021952	CP024833	CP026474	JQ837276	KF701335	KJ933392
MF344563	MF042356	KY882285	KY093014	KX711880	KU862632	KU167609	KR559890	KJ958926
MF344564	MF042357	KY887590	KY130431	KX756453	KU886034	KU295131	KR822247	KJ958927
MF344565	MF042358	KY887591	KY270849	KX783439	KU934011	KU295132	KT148595	KM400601
MF344566	MF042359	KY887594	KY270850	KX783440	KX023261	KU295133	KT185451	KM877517
MF344567	MF133495	KY887595	KY271403	KX783441	KX062091	KU295134	KT345946	KM977631
MF344574	MF150120	KY887596	KY271413	KX786648	KX094555	KU295135	KT345947	KP125892
MF511773	MF156708	KY930324	KY271414	KX833071	KX154765	KU295136	KT725788	KP345882
MF547507	MF156709	KY930325	KY271415	KX868553	KX236178	KU302800	KT725789	KP776609
MF547508	MF156711	KY978631	KY288024	KX881941	KX276209	KU302801	KT982613	KP868646
MF547509	MF156713	LT009688	KY399972	KX928750	KX348144	KU302802	KT982615	KP868647
MF547510	MF168402	LT009689	KY399973	KX928751	KX348145	KU314941	KT982616	KP893385
MF547511	MF168403	LT216438	KY399974	KX928752	KX348146	KU318419	KT982618	KP900015
MF582638	MF168404	LT838197	KY399975	KX960109	KX397572	KU318421	KT989376	KP987218
MF679143	MF168405	MF042350	KY435936	KX960110	KX447767	KU647721	KT989598	KR059864
MF679147	MF168406	MF042351	KY463220	KY020154	KX470734	KU665641	KU051707	KR091915
MG049738	MF178139	MF042352	KY798505	KY041843	KX507346	KU665642	KU051708	KR351290
MG053313	MF344561	MF042353	KY798506	KY062156	KX674681	KU726588	KU051709	KR559888
MG271839	MF344562	MF042354	KY798507	KY093013	KX683284	KU761328	KU167608	KR559889
MG516907	MG516908	MG516909	MG516910	MG557998	MG557999	AM778842	CP011370	KC189475
KC543497	KC609322	KC609323	KP873172	KP975076	KU578314	KX169264	KX711879	KX889311
KY296095	KY494864	KY630469	MF168945	MF344578				

APPENDIX D

TABLE 5: Percent of plasmids belonging to each incompatibility group.

Percent of plasmids	Inc Group	Percent of plasmids	Inc Group
0.22%	IncA/C	13.68%	IncN
11.88%	IncA/C2	0.67%	IncN2
0.22%	IncB/O/K/Z	0.67%	IncN3
0.67%	Col	0.22%	IncP1
1.35%	Col440I	0.90%	IncP6
1.79%	ColRNAI	1.35%	IncQ1
4.71%	IncFIA	0.22%	IncQ2
12.78%	IncFIB	8.97%	IncR
19.73%	IncFII	2.24%	repA
2.24%	IncHI1B	1.79%	IncU
0.45%	IncHI2	13.23%	IncX3
0.45%	IncHI2A	0.22%	IncX4
0.22%	IncI1	0.90%	IncX5
0.90%	IncI2	0.67%	IncX6
2.69%	IncL/M	0.90%	IncY
		7.62%	Unclassified

(Note: Total is greater than 100% because some plasmids have multiple incompatibility groups)

## APPENDIX E

TABLE 6: Relative abundance of incompatibility groups among carbapenemase-carrying plasmids.

**Supplementary Table 4:** Relative abundance of incompatibility groups among carbapenemase-carrying plasmids.

Carbapenemase	Incompatibility Groups (Percent of plasmids)										
Family	IncA/C	IncA/C2	IncB/O/K/Z	Col	Col440I	ColRNAI	IncFIA	IncFIB	IncFII	IncHIIB	IncHI2
KPC	0.0%	4.0%	0.0%	0.0%	2.5%	4.0%	5.6%	18.2%	20.2%	0.0%	0.0%
NDM	0.0%	17.9%	0.6%	0.0%	0.0%	0.0%	6.0%	10.7%	28.0%	6.0%	0.0%
IMP	0.0%	22.4%	0.0%	0.0%	0.0%	0.0%	0.0%	2.0%	2.0%	0.0%	4.1%
VIM	3.2%	16.1%	0.0%	9.7%	3.2%	0.0%	0.0%	6.5%	3.2%	0.0%	0.0%
	IncHI2A	IncI1	IncI2	IncL/M	IncN	IncN2	IncN3	IncP1	IncP6	IncQ1	IncQ2
KPC	0.0%	0.0%	2.0%	2.5%	17.7%	0.0%	1.0%	0.5%	1.5%	1.5%	0.5%
NDM	0.0%	0.0%	0.0%	1.2%	3.0%	1.8%	0.0%	0.0%	0.0%	1.8%	0.0%
IMP	4.1%	2.0%	0.0%	10.2%	34.7%	0.0%	2.0%	0.0%	0.0%	0.0%	0.0%
VIM	0.0%	0.0%	0.0%	0.0%	12.9%	0.0%	0.0%	0.0%	3.2%	0.0%	0.0%
	IncR	repA	IncU	IncX3	IncX4	IncX5	IncX6	IncY	NA		
KPC	13.6%	5.1%	2.5%	5.6%	0.0%	1.5%	1.5%	1.5%	5.6%		
NDM	4.8%	0.0%	0.0%	29.2%	0.6%	0.0%	0.0%	0.6%	2.4%		
IMP	2.0%	0.0%	6.1%	0.0%	0.0%	2.0%	0.0%	2.0%	16.3%		
VIM	12.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	35.5%		

Note: Totals are greater than 100% because some plasmids carry more than one replicon type.